Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Parkinson's Disease

  Free Subscription


Articles published in Mov Disord

Retrieve available abstracts of 562 articles:
HTML format



Single Articles


    November 2021
  1. WERNER MH, Olanow CW
    Parkinson's Disease Modification through Abl Kinase Inhibition: An Opportunity.
    Mov Disord. 2021 Nov 23. doi: 10.1002/mds.28858.
    PubMed     Abstract available


  2. SCAMARCIA PG, Agosta F, Spinelli EG, Basaia S, et al
    Longitudinal White Matter Damage Evolution in Parkinson's Disease.
    Mov Disord. 2021 Nov 22. doi: 10.1002/mds.28864.
    PubMed     Abstract available


  3. SASIKUMAR S, Cohn M, Harmsen IE, Loh A, et al
    Single-Trajectory Multiple-Target Deep Brain Stimulation for Parkinsonian Mobility and Cognition.
    Mov Disord. 2021 Nov 22. doi: 10.1002/mds.28870.
    PubMed     Abstract available


  4. CHEN C, Mossman E, Malko P, McDonald D, et al
    Astrocytic Changes in Mitochondrial Oxidative Phosphorylation Protein Levels in Parkinson's Disease.
    Mov Disord. 2021 Nov 15. doi: 10.1002/mds.28849.
    PubMed     Abstract available


  5. COSENTINO C, Torres L, Velez M, Nunez Y, et al
    SARS-CoV-2 Vaccines and Motor Symptoms in Parkinson's Disease.
    Mov Disord. 2021 Nov 14. doi: 10.1002/mds.28851.
    PubMed    


  6. VOGEL A, Claus I, Ahring S, Gruber D, et al
    Endoscopic Characteristics of Dysphagia in Multiple System Atrophy Compared to Parkinson's Disease.
    Mov Disord. 2021 Nov 13. doi: 10.1002/mds.28854.
    PubMed     Abstract available


  7. LANE EL, Harrison DJ, Ramos-Varas E, Hills R, et al
    Spontaneous Graft-Induced Dyskinesias Are Independent of 5-HT Neurons and Levodopa Priming in a Model of Parkinson's Disease.
    Mov Disord. 2021 Nov 12. doi: 10.1002/mds.28856.
    PubMed     Abstract available


  8. SURMEIER DJ, Nguyen JT, Lancki N, Venuto CS, et al
    Re-Analysis of the STEADY-PD II Trial-Evidence for Slowing the Progression of Parkinson's Disease.
    Mov Disord. 2021 Nov 12. doi: 10.1002/mds.28850.
    PubMed     Abstract available


  9. SURFACE M, Balwani M, Waters C, Haimovich A, et al
    Plasma Glucosylsphingosine in GBA1 Mutation Carriers with and without Parkinson's Disease.
    Mov Disord. 2021 Nov 6. doi: 10.1002/mds.28846.
    PubMed     Abstract available


  10. ARPIN DJ, Mitchell T, Archer DB, Burciu RG, et al
    Diffusion Magnetic Resonance Imaging Detects Progression in Parkinson's Disease: A Placebo-Controlled Trial of Rasagiline.
    Mov Disord. 2021 Nov 1. doi: 10.1002/mds.28838.
    PubMed     Abstract available


    October 2021
  11. CORVOL JC, Azulay JP, Bosse B, Dauvilliers Y, et al
    THN 102 for Excessive Daytime Sleepiness Associated with Parkinson's Disease: A Phase 2a Trial.
    Mov Disord. 2021 Oct 28. doi: 10.1002/mds.28840.
    PubMed     Abstract available


  12. CHARISIS S, Ntanasi E, Stamelou M, Xiromerisiou G, et al
    Plasma Glutathione and Prodromal Parkinson's Disease Probability.
    Mov Disord. 2021 Oct 25. doi: 10.1002/mds.28826.
    PubMed     Abstract available


  13. VAN RENSBURG ZJ, Abrahams S, Chetty D, Step K, et al
    The South African Parkinson's Disease Study Collection.
    Mov Disord. 2021 Oct 22. doi: 10.1002/mds.28828.
    PubMed     Abstract available


  14. SAMBIN S, Lavisse S, Decaix C, Pyatigorskaya N, et al
    Compensatory Mechanisms Nine Years Before Parkinson's Disease Conversion in a LRRK2 R1441H Family.
    Mov Disord. 2021 Oct 20. doi: 10.1002/mds.28833.
    PubMed    


  15. KLARENDIC M, Kirbis M, Mojsovska E, Kavcic M, et al
    Bee Venom Does Not Reduce the Risk for Parkinson's Disease: Epidemiological Study among Beekeepers.
    Mov Disord. 2021 Oct 16. doi: 10.1002/mds.28820.
    PubMed     Abstract available


  16. TSUKITA K, Sakamaki-Tsukita H, Takahashi R
    Lower Circulating Lymphocyte Count Predicts ApoE epsilon4-Related Cognitive Decline in Parkinson's Disease.
    Mov Disord. 2021 Oct 13. doi: 10.1002/mds.28799.
    PubMed    


  17. HUXFORD B, Haque T, Joseph AB, Simonet C, et al
    Parkinson's Disease and Type 2 Diabetes: HbA1c Is Associated with Motor and Cognitive Severity.
    Mov Disord. 2021 Oct 13. doi: 10.1002/mds.28829.
    PubMed    


  18. JARAZO J, Barmpa K, Modamio J, Saraiva C, et al
    Parkinson's Disease Phenotypes in Patient Neuronal Cultures and Brain Organoids Improved by 2-Hydroxypropyl-beta-Cyclodextrin Treatment.
    Mov Disord. 2021 Oct 12. doi: 10.1002/mds.28810.
    PubMed     Abstract available


  19. SCHIRINZI T, Maftei D, Ralli M, Greco A, et al
    Serum Substance P Is Increased in Parkinson's Disease and Correlates with Motor Impairment.
    Mov Disord. 2021 Oct 8. doi: 10.1002/mds.28824.
    PubMed    


  20. MAGRINELLI F, Mehta S, Di Lazzaro G, Latorre A, et al
    Dissecting the Phenotype and Genotype of PLA2G6-Related Parkinsonism.
    Mov Disord. 2021 Oct 8. doi: 10.1002/mds.28807.
    PubMed     Abstract available


  21. PU JL, Jin CY, Wang ZX, Fang Y, et al
    Apolipoprotein E Genotype Contributes to Motor Progression in Parkinson's Disease.
    Mov Disord. 2021 Oct 6. doi: 10.1002/mds.28805.
    PubMed     Abstract available


  22. PIHLSTROM L, Fan CC, Frei O, Tan M, et al
    Genetic Stratification of Age-Dependent Parkinson's Disease Risk by Polygenic Hazard Score.
    Mov Disord. 2021 Oct 6. doi: 10.1002/mds.28808.
    PubMed     Abstract available


  23. JUCAITE A, Cselenyi Z, Kreisl WC, Rabiner EA, et al
    Glia Imaging Differentiates Multiple System Atrophy from Parkinson's Disease: A Positron Emission Tomography Study with [(11) C]PBR28 and Machine Learning Analysis.
    Mov Disord. 2021 Oct 5. doi: 10.1002/mds.28814.
    PubMed     Abstract available


  24. GULER S, Gul T, Guler S, Haerle MC, et al
    Early-Onset Parkinson's Disease: A Novel Deletion Comprising the DJ-1 and TNFRSF9 Genes.
    Mov Disord. 2021 Oct 3. doi: 10.1002/mds.28812.
    PubMed     Abstract available


  25. CAMINITI SP, Carli G, Avenali M, Blandini F, et al
    Clinical and Dopamine Transporter Imaging Trajectories in a Cohort of Parkinson's Disease Patients with GBA Mutations.
    Mov Disord. 2021 Oct 1. doi: 10.1002/mds.28818.
    PubMed     Abstract available


  26. KANG X, Ploner A, Roelstraete B, Khalili H, et al
    Reply to: "Association between Microscopic Colitis and Parkinson's Disease in a Swedish Population".
    Mov Disord. 2021;36:2453.
    PubMed    


  27. ONG TL, Dal S, Williams LJ, Morales-Briceno H, et al
    \Association between Microscopic Colitis and Parkinson's Disease in a Swedish Population.
    Mov Disord. 2021;36:2452.
    PubMed    


  28. GAN-OR Z, Wood NW
    Mendelian Randomization Studies: A Path to Better Understand Sex and Gender Differences in Parkinson's Disease?
    Mov Disord. 2021;36:2220-2222.
    PubMed    


  29. NAMBU A
    Distinct Roles of the Dorsal Versus Ventral Subthalamic Nucleus.
    Mov Disord. 2021;36:2223.
    PubMed    


  30. ERRO R, Mencacci NE, Bhatia KP
    The Emerging Role of Phosphodiesterases in Movement Disorders.
    Mov Disord. 2021;36:2225-2243.
    PubMed     Abstract available


    September 2021
  31. REYES-PEREZ P, Bandres-Ciga S
    Identifying Genetic Markers Associated with the Progression of Cognitive Decline in Parkinson's Disease: A Call Out for Replication.
    Mov Disord. 2021 Sep 30. doi: 10.1002/mds.28798.
    PubMed    


  32. MILANOWSKI LM, Oshinaike O, Walton RL, Soto-Beasley AI, et al
    Screening of GBA Mutations in Nigerian Patients with Parkinson's Disease.
    Mov Disord. 2021 Sep 29. doi: 10.1002/mds.28803.
    PubMed    


  33. EVIDENTE VGH, Evidente DH, Ortega SC, Levine TD, et al
    X-Linked Dystonia-Parkinsonism ("Lubag") May Present with Peripheral Synucleinopathy.
    Mov Disord. 2021 Sep 28. doi: 10.1002/mds.28801.
    PubMed     Abstract available


  34. REN Y, Jiang H, Pu J, Li L, et al
    Molecular Features of Parkinson's Disease in Patient-Derived Midbrain Dopaminergic Neurons.
    Mov Disord. 2021 Sep 26. doi: 10.1002/mds.28786.
    PubMed     Abstract available


  35. BUCHANAN SM, Richards M, Schott JM, Schrag A, et al
    Mild Parkinsonian Signs: A Systematic Review of Clinical, Imaging, and Pathological Associations.
    Mov Disord. 2021 Sep 25. doi: 10.1002/mds.28777.
    PubMed     Abstract available


  36. MAASS F, Michalke B, Willkommen D, Canaslan S, et al
    Cerebrospinal Fluid Iron-Ferritin Ratio as a Potential Progression Marker for Parkinson's Disease.
    Mov Disord. 2021 Sep 23. doi: 10.1002/mds.28790.
    PubMed     Abstract available


  37. OMER N, Giladi N, Gurevich T, Bar-Shira A, et al
    Glucocerebrosidase Activity is not Associated with Parkinson's Disease Risk or Severity.
    Mov Disord. 2021 Sep 22. doi: 10.1002/mds.28792.
    PubMed     Abstract available


  38. LAKE J, Reed X, Langston RG, Nalls MA, et al
    Coding and Noncoding Variation in LRRK2 and Parkinson's Disease Risk.
    Mov Disord. 2021 Sep 20. doi: 10.1002/mds.28787.
    PubMed     Abstract available


  39. RENNER H, Scholer HR, Bruder JM
    Combining Automated Organoid Workflows With Artificial Intelligence-Based Analyses: Opportunities to Build a New Generation of Interdisciplinary High-Throughput Screens for Parkinson's Disease and Beyond.
    Mov Disord. 2021 Sep 8. doi: 10.1002/mds.28775.
    PubMed     Abstract available


  40. POEWE W, Stocchi F, Arkadir D, Ebersbach G, et al
    Subcutaneous Levodopa Infusion for Parkinson's Disease: 1-Year Data from the Open-Label BeyoND Study.
    Mov Disord. 2021 Sep 8. doi: 10.1002/mds.28758.
    PubMed     Abstract available


  41. MAILLET A, Metereau E, Tremblay L, Favre E, et al
    Serotonergic and Dopaminergic Lesions Underlying Parkinsonian Neuropsychiatric Signs.
    Mov Disord. 2021 Sep 8. doi: 10.1002/mds.28722.
    PubMed     Abstract available


  42. AAMODT WW, Waligorska T, Shen J, Tropea TF, et al
    Neurofilament Light Chain as a Biomarker for Cognitive Decline in Parkinson Disease.
    Mov Disord. 2021 Sep 4. doi: 10.1002/mds.28779.
    PubMed     Abstract available


  43. LIN ZH, Zhang BR
    Striking While the Iron is Hot: The Role of Prosaposin (PSAP) in Parkinson's Disease.
    Mov Disord. 2021 Sep 3. doi: 10.1002/mds.28781.
    PubMed    


  44. ELSAYED I, Foote IF
    Improving Diversity in Parkinson's Disease Genetics: Findings from the First-Ever Genome-Wide Association Study in Latinos.
    Mov Disord. 2021 Sep 2. doi: 10.1002/mds.28782.
    PubMed    


  45. TERRACCIANO A, Aschwanden D, Stephan Y, Cerasa A, et al
    Reply to: "Is Conscientiousness Related to the Risk of Parkinson's Disease?"
    Mov Disord. 2021;36:2216.
    PubMed    


  46. LUCA A, Nicoletti A, Zappia M
    Neuroticism and Risk of Parkinson's Disease: A Meta-Analysis.
    Mov Disord. 2021;36:2215.
    PubMed    


  47. QUATTRONE A, Antonini A, Vaillancourt DE, Seppi K, et al
    Reply to: "Experience with a New Index to Differentiate Parkinson's Disease and Progressive Supranuclear Palsy".
    Mov Disord. 2021;36:2208-2209.
    PubMed    


  48. LIU H, Koros C, Stefanis L, Gasser T, et al
    Reply to: "alpha-Synuclein (SNCA) A30G Mutation as a Cause of a Complex Phenotype Without Parkinsonism".
    Mov Disord. 2021;36:2212-2213.
    PubMed    


  49. RAU A, Jost WH, von der Warth R, Urbach H, et al
    Experience with a New Index to Differentiate Parkinson's Disease and Progressive Supranuclear Palsy.
    Mov Disord. 2021;36:2207-2208.
    PubMed    


  50. TAN S, Baggio D, Shortt J, Ko B, et al
    Cardiovascular Safety of Nilotinib in Parkinson's Disease.
    Mov Disord. 2021;36:2217.
    PubMed    


  51. SOKRATOUS M, Breza M, Senkevich K, Gan-Or Z, et al
    alpha-Synuclein (SNCA) A30G Mutation as a Cause of a Complex Phenotype Without Parkinsonism.
    Mov Disord. 2021;36:2209-2212.
    PubMed    


  52. ISHIMOTO T, Yamakado H
    Membranes and Organelle in Lewy Bodies: The Mastermind or the Bystander?
    Mov Disord. 2021;36:2026.
    PubMed    


  53. MAJBOUR NK, Abdi IY, Dakna M, Wicke T, et al
    Cerebrospinal alpha-Synuclein Oligomers Reflect Disease Motor Severity in DeNoPa Longitudinal Cohort.
    Mov Disord. 2021;36:2048-2056.
    PubMed     Abstract available


  54. ANDERSEN KB, Hansen AK, Damholdt MF, Horsager J, et al
    Reduced Synaptic Density in Patients with Lewy Body Dementia: An [(11) C]UCB-J PET Imaging Study.
    Mov Disord. 2021;36:2057-2065.
    PubMed     Abstract available


    August 2021
  55. LIU Y, Lawton MA, Lo C, Bowring F, et al
    Longitudinal Changes in Parkinson's Disease Symptoms with and Without Rapid Eye Movement Sleep Behavior Disorder: The Oxford Discovery Cohort Study.
    Mov Disord. 2021 Aug 26. doi: 10.1002/mds.28763.
    PubMed     Abstract available


  56. KAINAGA M, Shirota Y, Kodama S, Toda T, et al
    Effects of the Coronavirus Disease 2019 Pandemic on Motor Symptoms in Parkinson's Disease: An Observational Study.
    Mov Disord. 2021 Aug 25. doi: 10.1002/mds.28766.
    PubMed    


  57. ONOFRJ M, Di Iorio A, Carrarini C, Russo M, et al
    Preexisting Bipolar Disorder Influences the Subsequent Phenotype of Parkinson's Disease.
    Mov Disord. 2021 Aug 24. doi: 10.1002/mds.28745.
    PubMed     Abstract available


  58. KUSTERS CDJ, Paul KC, Duarte Folle A, Keener AM, et al
    Increased Menopausal Age Reduces the Risk of Parkinson's Disease: A Mendelian Randomization Approach.
    Mov Disord. 2021 Aug 23. doi: 10.1002/mds.28760.
    PubMed     Abstract available


  59. CAMPESE N, Goebel G, Leys F, Ndayisaba JP, et al
    Orthostatic Hypotension in Parkinson's Disease: Do Height and Weight Matter?
    Mov Disord. 2021 Aug 23. doi: 10.1002/mds.28768.
    PubMed    


  60. O'SHEA SA, Hickman RA, Cortes E, Vonsattel JP, et al
    Neuropathological Findings in a Case of Parkinsonism and Developmental Delay Associated with a Monoallelic Variant in PLXNA1.
    Mov Disord. 2021 Aug 20. doi: 10.1002/mds.28756.
    PubMed     Abstract available


  61. CIRNARU MD, Creus-Muncunill J, Nelson S, Lewis T, et al
    Striatal Cholinergic Dysregulation after Neonatal Decrease in X-Linked Dystonia Parkinsonism-Related TAF1 Isoforms.
    Mov Disord. 2021 Aug 17. doi: 10.1002/mds.28750.
    PubMed     Abstract available


  62. SIA MW, Foo JN, Saffari SE, Wong AS, et al
    Polygenic Risk Scores in a Prospective Parkinson's Disease Cohort.
    Mov Disord. 2021 Aug 17. doi: 10.1002/mds.28761.
    PubMed     Abstract available


  63. QI S, Yin P, Wang L, Qu M, et al
    Prevalence of Parkinson's Disease: A Community-Based Study in China.
    Mov Disord. 2021 Aug 14. doi: 10.1002/mds.28762.
    PubMed     Abstract available


  64. GARCIA AM, Arias-Vergara T, C Vasquez-Correa J, Noth E, et al
    Cognitive Determinants of Dysarthria in Parkinson's Disease: An Automated Machine Learning Approach.
    Mov Disord. 2021 Aug 14. doi: 10.1002/mds.28751.
    PubMed     Abstract available


  65. LE HERON C, MacAskill M, Mason D, Dalrymple-Alford J, et al
    A Multi-Step Model of Parkinson's Disease Pathogenesis.
    Mov Disord. 2021 Aug 10. doi: 10.1002/mds.28719.
    PubMed     Abstract available


  66. ERRO R, Buonomo AR, Barone P, Pellecchia MT, et al
    Severe dyskinesia after administration of SARS-CoV2 mRNA vaccine in Parkinson Disease.
    Mov Disord. 2021 Aug 9. doi: 10.1002/mds.28772.
    PubMed    


  67. OLANOW CW, Poewe W, Rascol O, Stocchi F, et al
    On-Demand Therapy for OFF Episodes in Parkinson's Disease.
    Mov Disord. 2021 Aug 7. doi: 10.1002/mds.28726.
    PubMed     Abstract available


  68. SCHAEFFER E, Toedt I, Kohler S, Rogge A, et al
    Risk Disclosure in Prodromal Parkinson's Disease.
    Mov Disord. 2021 Aug 5. doi: 10.1002/mds.28723.
    PubMed     Abstract available


  69. OKUNOYE O, Horsfall L, Marston L, Walters K, et al
    Mortality of People with Parkinson's Disease in a Large UK-Based Cohort Study: Time Trends and Relationship to Disease Duration.
    Mov Disord. 2021 Aug 5. doi: 10.1002/mds.28727.
    PubMed     Abstract available


  70. MARKAKI I, Ntetsika T, Svenningsson P
    Reply to: "HbA1c and Motor Outcome in Parkinson's Disease in the Mark-PD Study".
    Mov Disord. 2021;36:1993.
    PubMed    


  71. MONJE MHG, Sanchez-Ferro A, Pineda-Pardo JA, Vela-Desojo L, et al
    Reply to: Motor Features in a Peruvian Cohort of Parkinson's Disease Patients.
    Mov Disord. 2021;36:1994-1995.
    PubMed    


  72. TORRES L, Velez M, Suarez R, Nunez Y, et al
    Motor Features in a Peruvian Cohort of Parkinson's Disease Patients.
    Mov Disord. 2021;36:1994.
    PubMed    


  73. ZITTEL S, Uyar M, Lezius S, Gerloff C, et al
    HbA1c and Motor Outcome in Parkinson's Disease in the Mark-PD Study.
    Mov Disord. 2021;36:1991-1992.
    PubMed    


  74. ZECH M, Jech R, Boesch S, Skorvanek M, et al
    Scoring Algorithm-Based Genomic Testing in Dystonia: A Prospective Validation Study.
    Mov Disord. 2021;36:1959-1964.
    PubMed     Abstract available


  75. KOSS DJ, Campesan S, Giorgini F, Outeiro TF, et al
    Dysfunction of RAB39B-Mediated Vesicular Trafficking in Lewy Body Diseases.
    Mov Disord. 2021;36:1744-1758.
    PubMed     Abstract available


  76. FASANO A, Gurevich T, Jech R, Kovacs N, et al
    Concomitant Medication Usage with Levodopa-Carbidopa Intestinal Gel: Results from the COSMOS Study.
    Mov Disord. 2021;36:1853-1862.
    PubMed     Abstract available


  77. KIM R, Lee JY, Kim YK, Kim H, et al
    Longitudinal Changes in Isolated Rapid Eye Movement Sleep Behavior Disorder-Related Metabolic Pattern Expression.
    Mov Disord. 2021;36:1889-1898.
    PubMed     Abstract available


    July 2021
  78. REN X, Lin J, Stebbins GT, Goetz CG, et al
    Prognostic Modeling of Parkinson's Disease Progression Using Early Longitudinal Patterns of Change.
    Mov Disord. 2021 Jul 30. doi: 10.1002/mds.28730.
    PubMed     Abstract available


  79. LAANSMA MA, Bright JK, Al-Bachari S, Anderson TJ, et al
    International Multicenter Analysis of Brain Structure Across Clinical Stages of Parkinson's Disease.
    Mov Disord. 2021 Jul 20. doi: 10.1002/mds.28706.
    PubMed     Abstract available


  80. SARASSO E, Agosta F, Piramide N, Gardoni A, et al
    Action Observation and Motor Imagery Improve Dual Task in Parkinson's Disease: A Clinical/fMRI Study.
    Mov Disord. 2021 Jul 19. doi: 10.1002/mds.28717.
    PubMed     Abstract available


  81. GROS P, Wang X, Guan J, Lang AE, et al
    Exposure to Phosphoglycerate Kinase 1 Activators and Incidence of Parkinson's Disease.
    Mov Disord. 2021 Jul 9. doi: 10.1002/mds.28712.
    PubMed     Abstract available


  82. CONCHA-MARAMBIO L, Farris CM, Holguin B, Ma Y, et al
    Seed Amplification Assay to Diagnose Early Parkinson's and Predict Dopaminergic Deficit Progression.
    Mov Disord. 2021 Jul 8. doi: 10.1002/mds.28715.
    PubMed    


  83. FREIRE-ALVAREZ E, Kurca E, Lopez Manzanares L, Pekkonen E, et al
    Levodopa-Carbidopa Intestinal Gel Reduces Dyskinesia in Parkinson's Disease in a Randomized Trial.
    Mov Disord. 2021 Jul 8. doi: 10.1002/mds.28703.
    PubMed     Abstract available


  84. MULLER-NEDEBOCK AC, Komolafe MA, Fawale MB, Carr JA, et al
    Copy Number Variation in Parkinson's Disease: An Update from Sub-Saharan Africa.
    Mov Disord. 2021 Jul 6. doi: 10.1002/mds.28710.
    PubMed    


  85. SCHILLING M, Lill CM
    MicroRNAs as Molecular Biomarkers for Parkinson's Disease Progression.
    Mov Disord. 2021 Jul 5. doi: 10.1002/mds.28700.
    PubMed    


  86. CHOONG CJ, Kimura Y, Mochizuki H
    Disturbed Mitochondria-Lysosome Crosstalk in GBA1-Associated Parkinson's Disease.
    Mov Disord. 2021 Jul 1. doi: 10.1002/mds.28693.
    PubMed    


  87. RASCOL O, Cochen de Cock V, Pavy-Le Traon A, Foubert-Samier A, et al
    Fluoxetine for the Symptomatic Treatment of Multiple System Atrophy: The MSA-FLUO Trial.
    Mov Disord. 2021;36:1704-1711.
    PubMed     Abstract available


  88. SHILL HA, Zhang N, Driver-Dunckley E, Mehta S, et al
    Olfaction in Neuropathologically Defined Progressive Supranuclear Palsy.
    Mov Disord. 2021;36:1700-1704.
    PubMed     Abstract available


  89. PERKINS JE, Janzen A, Bernhard FP, Wilhelm K, et al
    Saccade, Pupil, and Blink Responses in Rapid Eye Movement Sleep Behavior Disorder.
    Mov Disord. 2021;36:1720-1726.
    PubMed     Abstract available


  90. DE ALMEIDA CMO, Brito MMC, Bosaipo NB, Pimentel AV, et al
    Cannabidiol for Rapid Eye Movement Sleep Behavior Disorder.
    Mov Disord. 2021;36:1711-1715.
    PubMed     Abstract available


  91. WITTKE C, Petkovic S, Dobricic V, Schaake S, et al
    Genotype-Phenotype Relations for the Atypical Parkinsonism Genes: MDSGene Systematic Review.
    Mov Disord. 2021;36:1499-1510.
    PubMed     Abstract available


    June 2021
  92. VIDENOVIC A, Amara AW, Comella C, Schweitzer PK, et al
    Solriamfetol for Excessive Daytime Sleepiness in Parkinson's Disease: Phase 2 Proof-of-Concept Trial.
    Mov Disord. 2021 Jun 30. doi: 10.1002/mds.28702.
    PubMed     Abstract available


  93. PATEL SG, Buchanan CM, Mulroy E, Simpson M, et al
    Potential PINK1 Founder Effect in Polynesia Causing Early-Onset Parkinson's Disease.
    Mov Disord. 2021 Jun 22. doi: 10.1002/mds.28665.
    PubMed    


  94. FIORENZATO E, Antonini A, Bisiacchi P, Weis L, et al
    Asymmetric Dopamine Transporter Loss Affects Cognitive and Motor Progression in Parkinson's Disease.
    Mov Disord. 2021 Jun 14. doi: 10.1002/mds.28682.
    PubMed     Abstract available


  95. NIGAM M, Ayadi I, Noiray C, Branquino-Bras AC, et al
    Sweet or Bland Dreams? Taste Loss in Isolated REM-Sleep Behavior Disorder and Parkinson's Disease.
    Mov Disord. 2021 Jun 12. doi: 10.1002/mds.28692.
    PubMed     Abstract available


  96. GELPI E, Haberler C, Micko A, Polt A, et al
    Focal Subthalamic Atrophy After Long-Term Deep Brain Stimulation in Parkinson's Disease.
    Mov Disord. 2021 Jun 12. doi: 10.1002/mds.28653.
    PubMed    


  97. MAITI B, Rawson KS, Tanenbaum AB, Koller JM, et al
    Functional Connectivity of Vermis Correlates with Future Gait Impairments in Parkinson's Disease.
    Mov Disord. 2021 Jun 10. doi: 10.1002/mds.28684.
    PubMed     Abstract available


  98. MUNOZ-DELGADO L, Macias-Garcia D, Jesus S, Martin-Rodriguez JF, et al
    Peripheral Immune Profile and Neutrophil-to-Lymphocyte Ratio in Parkinson's Disease.
    Mov Disord. 2021 Jun 8. doi: 10.1002/mds.28685.
    PubMed     Abstract available


  99. SEGER AD, Farrher E, Doppler CEJ, Gogishvili A, et al
    Putaminal y-Aminobutyric Acid Modulates Motor Response to Dopaminergic Therapy in Parkinson's Disease.
    Mov Disord. 2021 Jun 7. doi: 10.1002/mds.28674.
    PubMed     Abstract available


  100. HAMID E, Ayele BA, Massi DG, Ben Sassi S, et al
    Availability of Therapies and Services for Parkinson's Disease in Africa: A Continent-Wide Survey.
    Mov Disord. 2021 Jun 3. doi: 10.1002/mds.28669.
    PubMed     Abstract available


  101. ISONAKA R, Goldstein DS, Zhu W, Yoon E, et al
    alpha-Synuclein Deposition in Sympathetic Nerve Fibers in Genetic Forms of Parkinson's Disease.
    Mov Disord. 2021 Jun 2. doi: 10.1002/mds.28667.
    PubMed     Abstract available


  102. MATHUR S
    Counting What Counts: How to Reach Outcomes That Truly Matter to Parkinson's Patients.
    Mov Disord. 2021;36:1290-1292.
    PubMed    


    May 2021
  103. CARVALHO V, Ferreira JJ, Correia Guedes L
    Tremor and Parkinsonism in Chromosomopathies - A Systematic Review.
    Mov Disord. 2021 May 31. doi: 10.1002/mds.28663.
    PubMed     Abstract available


  104. CONEYS R, Storm CS, Kia DA, Almramhi M, et al
    Mendelian Randomisation Finds No Causal Association between Urate and Parkinson's Disease Progression.
    Mov Disord. 2021 May 31. doi: 10.1002/mds.28662.
    PubMed     Abstract available


  105. FEARON C, Mikulis DJ, Lang AE
    Parkinsonism as a Sequela of SARS-CoV-2 Infection: Pure Hypoxic Injury or Additional COVID-19-Related Response?
    Mov Disord. 2021 May 27. doi: 10.1002/mds.28656.
    PubMed    


  106. BOUALI-BENAZZOUZ R, Benazzouz A
    Covid-19 Infection and Parkinsonism: Is There a Link?
    Mov Disord. 2021 May 27. doi: 10.1002/mds.28680.
    PubMed     Abstract available


  107. ORSO B, Arnaldi D, Girtler N, Brugnolo A, et al
    Dopaminergic and Serotonergic Degeneration and Cortical [(18) F]Fluorodeoxyglucose Positron Emission Tomography in De Novo Parkinson's Disease.
    Mov Disord. 2021 May 22. doi: 10.1002/mds.28654.
    PubMed     Abstract available


  108. DEAN DN, Lee JC
    Linking Parkinson's Disease and Melanoma: Interplay Between alpha-Synuclein and Pmel17 Amyloid Formation.
    Mov Disord. 2021 May 22. doi: 10.1002/mds.28655.
    PubMed     Abstract available


  109. SCHWEDHELM E, Englisch C, Niemann L, Lezius S, et al
    Sphingosine-1-Phosphate, Motor Severity, and Progression in Parkinson's Disease (MARK-PD).
    Mov Disord. 2021 May 19. doi: 10.1002/mds.28652.
    PubMed     Abstract available


  110. TOFFOLI M, Higgins A, Lee C, Koletsi S, et al
    Intronic Haplotypes in the GBA Gene Do Not Predict Age at Diagnosis of Parkinson's Disease.
    Mov Disord. 2021 May 19. doi: 10.1002/mds.28616.
    PubMed     Abstract available


  111. STUENDL A, Kraus T, Chatterjee M, Zapke B, et al
    alpha-Synuclein in Plasma-Derived Extracellular Vesicles Is a Potential Biomarker of Parkinson's Disease.
    Mov Disord. 2021 May 18. doi: 10.1002/mds.28639.
    PubMed     Abstract available


  112. O'SULLIVAN JM, den Heijer JM, Groeneveld GJ, Cooper AA, et al
    Intronic Haplotypes in GBA Modify Age at Diagnosis of Parkinson's: Replication in a Subgroup.
    Mov Disord. 2021 May 18. doi: 10.1002/mds.28620.
    PubMed    


  113. HAN F, Brown GL, Zhu Y, Belkin-Rosen AE, et al
    Decoupling of Global Brain Activity and Cerebrospinal Fluid Flow in Parkinson's Disease Cognitive Decline.
    Mov Disord. 2021 May 17. doi: 10.1002/mds.28643.
    PubMed     Abstract available


  114. MORLEY D, Dummett S, Kelly L, Jenkinson C, et al
    Development of an Exercise-Specific Parkinson's Disease Questionnaire: The PDQ-Exercise.
    Mov Disord. 2021 May 15. doi: 10.1002/mds.28644.
    PubMed     Abstract available


  115. MARRAS C, Mills KA, Eberly S, Oakes D, et al
    Longitudinal Change in Quality of Life in Neurological Disorders Measures Over 3 Years in Patients With Early Parkinson's Disease.
    Mov Disord. 2021 May 13. doi: 10.1002/mds.28641.
    PubMed     Abstract available


  116. RICCIARDI L, Fischer P, Mostofi A, Tinkhauser G, et al
    Neurophysiological Correlates of Trait Impulsivity in Parkinson's Disease.
    Mov Disord. 2021 May 13. doi: 10.1002/mds.28625.
    PubMed     Abstract available


  117. ESTIAR MA, Senkevich K, Yu E, Varghaei P, et al
    Lack of Causal Effects or Genetic Correlation between Restless Legs Syndrome and Parkinson's Disease.
    Mov Disord. 2021 May 11. doi: 10.1002/mds.28640.
    PubMed     Abstract available


  118. COLLOBY SJ, Nathan PJ, Bakker G, Lawson RA, et al
    Spatial Covariance of Cholinergic Muscarinic M1 /M4 Receptors in Parkinson's Disease.
    Mov Disord. 2021 May 11. doi: 10.1002/mds.28564.
    PubMed     Abstract available


  119. NAITO T, Satake W, Ogawa K, Suzuki K, et al
    Trans-Ethnic Fine-Mapping of the Major Histocompatibility Complex Region Linked to Parkinson's Disease.
    Mov Disord. 2021 May 11. doi: 10.1002/mds.28583.
    PubMed     Abstract available


  120. BARBUTI PA, Barker RA, Brundin P, Przedborski S, et al
    Recent Advances in the Development of Stem-Cell-Derived Dopaminergic Neuronal Transplant Therapies for Parkinson's Disease.
    Mov Disord. 2021 May 8. doi: 10.1002/mds.28628.
    PubMed     Abstract available


  121. IWAKI H, Leonard HL, Makarious MB, Bookman M, et al
    Accelerating Medicines Partnership: Parkinson's Disease. Genetic Resource.
    Mov Disord. 2021 May 7. doi: 10.1002/mds.28549.
    PubMed     Abstract available


  122. DI LAZZARO G, Magrinelli F, Estevez-Fraga C, Valente EM, et al
    X-Linked Parkinsonism: Phenotypic and Genetic Heterogeneity.
    Mov Disord. 2021 May 7. doi: 10.1002/mds.28565.
    PubMed     Abstract available


  123. MCINTOSH E, Kent S, Gray A, Clarke CE, et al
    Cost-Effectiveness of Dopamine Agonists and Monoamine Oxidase B Inhibitors in Early Parkinson's Disease.
    Mov Disord. 2021 May 7. doi: 10.1002/mds.28623.
    PubMed     Abstract available


  124. MIRELMAN A, Ben Or Frank M, Melamed M, Granovsky L, et al
    Detecting Sensitive Mobility Features for Parkinson's Disease Stages Via Machine Learning.
    Mov Disord. 2021 May 6. doi: 10.1002/mds.28631.
    PubMed     Abstract available


  125. KAASINEN V, Vahlberg T, Stoessl AJ, Strafella AP, et al
    Dopamine Receptors in Parkinson's Disease: A Meta-Analysis of Imaging Studies.
    Mov Disord. 2021 May 6. doi: 10.1002/mds.28632.
    PubMed     Abstract available


  126. KREMER T, Taylor KI, Siebourg-Polster J, Gerken T, et al
    Longitudinal Analysis of Multiple Neurotransmitter Metabolites in Cerebrospinal Fluid in Early Parkinson's Disease.
    Mov Disord. 2021 May 4. doi: 10.1002/mds.28608.
    PubMed     Abstract available


  127. SCHERBAUM R, Kwon EH, Richter D, Bartig D, et al
    Clinical Profiles and Mortality of COVID-19 Inpatients with Parkinson's Disease in Germany.
    Mov Disord. 2021 May 4. doi: 10.1002/mds.28586.
    PubMed     Abstract available


  128. MESTRE TA, Macklin EA, Ascherio A, Ferreira JJ, et al
    Expectations of Benefit in a Trial of a Candidate Disease-Modifying Treatment for Parkinson Disease.
    Mov Disord. 2021 May 4. doi: 10.1002/mds.28630.
    PubMed     Abstract available


  129. SCOTT GD, Lim MM, Drake MG, Woltjer R, et al
    Onset of Skin, Gut, and Genitourinary Prodromal Parkinson's Disease: A Study of 1.5 Million Veterans.
    Mov Disord. 2021 May 3. doi: 10.1002/mds.28636.
    PubMed     Abstract available


  130. KIEBURTZ K, Olanow CW
    Reply to: "A New Approach to the Development of Disease-Modifying Therapies for PD".
    Mov Disord. 2021;36:1281-1282.
    PubMed    


  131. SIMON DK
    A New Approach to the Development of Disease-Modifying Therapies for PD.
    Mov Disord. 2021;36:1281.
    PubMed    


  132. LERCHE S, Schulte C, Wurster I, Machetanz G, et al
    The Mutation Matters: CSF Profiles of GCase, Sphingolipids, alpha-Synuclein in PDGBA.
    Mov Disord. 2021;36:1216-1228.
    PubMed     Abstract available


    April 2021
  133. YILMAZ R, Suenkel U, Postuma RB, Heinzel S, et al
    Comparing the Two Prodromal Parkinson's Disease Research Criteria-Lessons for Future Studies.
    Mov Disord. 2021 Apr 30. doi: 10.1002/mds.28637.
    PubMed    


  134. SARANZA G, Villanueva EQ 3rd, Lang AE
    Preferences for Communication About End-of-Life Care in Atypical Parkinsonism.
    Mov Disord. 2021 Apr 28. doi: 10.1002/mds.28633.
    PubMed     Abstract available


  135. HUYNH B, Fu Y, Kirik D, Shine JM, et al
    Comparison of Locus Coeruleus Pathology with Nigral and Forebrain Pathology in Parkinson's Disease.
    Mov Disord. 2021 Apr 26. doi: 10.1002/mds.28615.
    PubMed     Abstract available


  136. TSUNEMI T, Oyama G, Saiki S, Hatano T, et al
    Intrajejunal Infusion of Levodopa/Carbidopa for Advanced Parkinson's Disease: A Systematic Review.
    Mov Disord. 2021 Apr 25. doi: 10.1002/mds.28595.
    PubMed     Abstract available


  137. LETA V, Rodriguez-Violante M, Abundes A, Rukavina K, et al
    Parkinson's disease and Post-COVID-19 syndrome: The Parkinson's Long-COVID spectrum.
    Mov Disord. 2021 Apr 22. doi: 10.1002/mds.28622.
    PubMed    


  138. LI C, Ou R, Chen Y, Gu X, et al
    Genetic Modifiers of Age at Onset for Parkinson's Disease in Asians: A Genome-Wide Association Study.
    Mov Disord. 2021 Apr 21. doi: 10.1002/mds.28621.
    PubMed     Abstract available


  139. CHEN Y, Wu W, Zhao S, Lv X, et al
    Increased Accumulation of alpha-Synuclein in Inflamed Appendices of Parkinson's Disease Patients.
    Mov Disord. 2021 Apr 20. doi: 10.1002/mds.28553.
    PubMed     Abstract available


  140. JOHNSON LA, Aman JE, Yu Y, Escobar Sanabria D, et al
    High-Frequency Oscillations in the Pallidum: A Pathophysiological Biomarker in Parkinson's Disease?
    Mov Disord. 2021 Apr 13. doi: 10.1002/mds.28566.
    PubMed     Abstract available


  141. SOARES C, Carneiro DR, Dias R, Ferreira D, et al
    Behind the mask: recognizing facial features of Parkinson's disease during the COVID-19 pandemic.
    Mov Disord. 2021 Apr 9. doi: 10.1002/mds.28619.
    PubMed    


  142. ZAHED H, Zuzuarregui JRP, Gilron R, Denison T, et al
    The Neurophysiology of Sleep in Parkinson's Disease.
    Mov Disord. 2021 Apr 7. doi: 10.1002/mds.28562.
    PubMed     Abstract available


  143. LIM SH, Ferdousi M, Kalteniece A, Mahfoud ZR, et al
    Corneal Confocal Microscopy Identifies Parkinson's Disease with More Rapid Motor Progression.
    Mov Disord. 2021 Apr 7. doi: 10.1002/mds.28602.
    PubMed     Abstract available


  144. JIANG C, Hopfner F, Berg D, Hu MT, et al
    Validation of alpha-Synuclein in L1CAM-Immunocaptured Exosomes as a Biomarker for the Stratification of Parkinsonian Syndromes.
    Mov Disord. 2021 Apr 7. doi: 10.1002/mds.28591.
    PubMed     Abstract available


  145. KOOHI N, Bancroft MJ, Patel J, Castro P, et al
    Saccadic Bradykinesia in Parkinson's Disease: Preliminary Observations.
    Mov Disord. 2021 Apr 6. doi: 10.1002/mds.28609.
    PubMed    


  146. TERRACCIANO A, Aschwanden D, Stephan Y, Cerasa A, et al
    Neuroticism and Risk of Parkinson's Disease: A Meta-Analysis.
    Mov Disord. 2021 Apr 4. doi: 10.1002/mds.28575.
    PubMed     Abstract available


  147. UEDA J, Uemura N, Sawamura M, Taguchi T, et al
    Perampanel Inhibits alpha-Synuclein Transmission in Parkinson's Disease Models.
    Mov Disord. 2021 Apr 4. doi: 10.1002/mds.28558.
    PubMed     Abstract available


  148. NIJHUIS FAP, Esselink R, de Bie RMA, Groenewoud H, et al
    Translating Evidence to Advanced Parkinson's Disease Patients: A Systematic Review and Meta-Analysis.
    Mov Disord. 2021 Apr 2. doi: 10.1002/mds.28599.
    PubMed     Abstract available


  149. HELMICH RC, Van den Berg KRE, Panyakaew P, Cho HJ, et al
    Cerebello-Cortical Control of Tremor Rhythm and Amplitude in Parkinson's Disease.
    Mov Disord. 2021 Apr 1. doi: 10.1002/mds.28603.
    PubMed    


  150. GUTTLER C, Nikulin VV, van Riesen C
    Reply to: "Levodopa-Induced Dyskinesia Is Mediated by Cortical Gamma Oscillations in Experimental Parkinsonism".
    Mov Disord. 2021;36:1045-1047.
    PubMed    


  151. SCHMIDT SL, Grill WM
    Levodopa-Induced Dyskinesia Is Mediated by Cortical Gamma Oscillations in Experimental Parkinsonism.
    Mov Disord. 2021;36:1044-1045.
    PubMed    


  152. NEUMANN WJ, Rodriguez-Oroz MC
    Machine Learning Will Extend the Clinical Utility of Adaptive Deep Brain Stimulation.
    Mov Disord. 2021;36:796-799.
    PubMed    


  153. RUSZ J, Tykalova T, Ramig LO, Tripoliti E, et al
    Guidelines for Speech Recording and Acoustic Analyses in Dysarthrias of Movement Disorders.
    Mov Disord. 2021;36:803-814.
    PubMed     Abstract available


  154. GEORGIEV D, Roskar S, Cus A, Wilkinson L, et al
    STN-DBS Increases Proactive but Not Retroactive Interference During Verbal Learning in PD.
    Mov Disord. 2021;36:1010-1015.
    PubMed     Abstract available


  155. OSHIMA S, Fushimi Y, Okada T, Nakajima S, et al
    Neuromelanin-Sensitive Magnetic Resonance Imaging Using DANTE Pulse.
    Mov Disord. 2021;36:874-882.
    PubMed     Abstract available


  156. BOOTH S, Ramadan A, Zhang D, Lu L, et al
    The Vasomotor Response to Dopamine Is Altered in the Rat Model of l-dopa-Induced Dyskinesia.
    Mov Disord. 2021;36:938-947.
    PubMed     Abstract available


    March 2021
  157. VISANJI NP, Lang AE
    Call the Plumber: Impaired Meningeal Lymphatic Drainage in Parkinson's Disease.
    Mov Disord. 2021 Mar 30. doi: 10.1002/mds.28590.
    PubMed    


  158. KLUGER BM, Dolhun R, Sumrall M, Hall K, et al
    Palliative Care and Parkinson's Disease: Time to Move Beyond Cancer.
    Mov Disord. 2021 Mar 30. doi: 10.1002/mds.28556.
    PubMed    


  159. SCHIESS M, Suescun J, Doursout MF, Adams C, et al
    Allogeneic Bone Marrow-Derived Mesenchymal Stem Cell Safety in Idiopathic Parkinson's Disease.
    Mov Disord. 2021 Mar 27. doi: 10.1002/mds.28582.
    PubMed     Abstract available


  160. KANG X, Ploner A, Roelstraete B, Khalili H, et al
    Association between Microscopic Colitis and Parkinson's Disease in a Swedish Population.
    Mov Disord. 2021 Mar 25. doi: 10.1002/mds.28594.
    PubMed     Abstract available


  161. GROVER S, Kumar-Sreelatha AA, Bobbili DR, May P, et al
    Replication of a Novel Parkinson's Locus in a European Ancestry Population.
    Mov Disord. 2021 Mar 24. doi: 10.1002/mds.28546.
    PubMed     Abstract available


  162. ABRAHAM DS, Pham Nguyen TP, Willis AW
    Claims-Based Frailty and Outcomes: Applying an Aging Measure to Older Adults with Parkinson's Disease.
    Mov Disord. 2021 Mar 23. doi: 10.1002/mds.28561.
    PubMed     Abstract available


  163. YAO CW, Saha-Chaudhuri P, Zolfaghari S, Pelletier A, et al
    Phenoconversion from Possible REM Sleep Behavior to Parkinsonism in the Population-Based CLSA.
    Mov Disord. 2021 Mar 22. doi: 10.1002/mds.28571.
    PubMed    


  164. SALARI M, Etemadifar M, Zali A, Medghalchi A, et al
    Seroprevalence of SARS-CoV-2 in Parkinson's Disease Patients: A Case-Control Study.
    Mov Disord. 2021 Mar 17. doi: 10.1002/mds.28580.
    PubMed    


  165. MARINI K, Seppi K, Tschiderer L, Kiechl S, et al
    Application of the Updated Movement Disorder Society Criteria for Prodromal Parkinson's Disease to a Population-Based 10-Year Study.
    Mov Disord. 2021 Mar 17. doi: 10.1002/mds.28570.
    PubMed    


  166. CANONICO M, Pesce G, Bonaventure A, Le Noan-Laine M, et al
    Increased Risk of Parkinson's Disease in Women after Bilateral Oophorectomy.
    Mov Disord. 2021 Mar 16. doi: 10.1002/mds.28563.
    PubMed     Abstract available


  167. DOBKIN RD, Mann SL, Weintraub D, Rodriguez KM, et al
    Innovating Parkinson's Care: A Randomized Controlled Trial of Telemedicine Depression Treatment.
    Mov Disord. 2021 Mar 12. doi: 10.1002/mds.28548.
    PubMed     Abstract available


  168. GAURAV R, Yahia-Cherif L, Pyatigorskaya N, Mangone G, et al
    Longitudinal Changes in Neuromelanin MRI Signal in Parkinson's Disease: A Progression Marker.
    Mov Disord. 2021 Mar 10. doi: 10.1002/mds.28531.
    PubMed     Abstract available


  169. CHOHAN H, Senkevich K, Patel RK, Bestwick JP, et al
    Type 2 Diabetes as a Determinant of Parkinson's Disease Risk and Progression.
    Mov Disord. 2021 Mar 8. doi: 10.1002/mds.28551.
    PubMed     Abstract available


  170. DUYSENS J, Nonnekes J
    Parkinson's Kinesia Paradoxa Is Not a Paradox.
    Mov Disord. 2021 Mar 3. doi: 10.1002/mds.28550.
    PubMed    


  171. CLAUS I, Muhle P, Czechowski J, Ahring S, et al
    Expiratory Muscle Strength Training for Therapy of Pharyngeal Dysphagia in Parkinson's Disease.
    Mov Disord. 2021 Mar 2. doi: 10.1002/mds.28552.
    PubMed     Abstract available


  172. FEARON C, Lang AE, Espay AJ
    The Logic and Pitfalls of Parkinson's Disease as "Brain-First" Versus "Body-First" Subtypes.
    Mov Disord. 2021;36:594-598.
    PubMed    


  173. BORGHAMMER P, Horsager J
    The Logic and Pitfalls of Parkinson's as Brain- Versus Body-First Subtypes.
    Mov Disord. 2021;36:785-786.
    PubMed    


  174. FEARON C, Lang AE, J Espay A
    Reply to: "The Logic and Pitfalls of Parkinson's as Brain- Versus Body-First Subtypes".
    Mov Disord. 2021;36:786-787.
    PubMed    


  175. SARTER M, Avila C, Kucinski A, Donovan E, et al
    Make a Left Turn: Cortico-Striatal Circuitry Mediating the Attentional Control of Complex Movements.
    Mov Disord. 2021;36:535-546.
    PubMed     Abstract available


  176. YOUNCE JR, Campbell MC, Hershey T, Tanenbaum AB, et al
    Resting-State Functional Connectivity Predicts STN DBS Clinical Response.
    Mov Disord. 2021;36:662-671.
    PubMed     Abstract available


  177. POLISSIDIS A, Koronaiou M, Kollia V, Koronaiou E, et al
    Psychosis-Like Behavior and Hyperdopaminergic Dysregulation in Human alpha-Synuclein BAC Transgenic Rats.
    Mov Disord. 2021;36:716-728.
    PubMed     Abstract available


  178. HANSS Z, Larsen SB, Antony P, Mencke P, et al
    Mitochondrial and Clearance Impairment in p.D620N VPS35 Patient-Derived Neurons.
    Mov Disord. 2021;36:704-715.
    PubMed     Abstract available


    February 2021
  179. DE MICCO R, Agosta F, Basaia S, Siciliano M, et al
    Functional Connectomics and Disease Progression in Drug-Naive Parkinson's Disease Patients.
    Mov Disord. 2021 Feb 27. doi: 10.1002/mds.28541.
    PubMed     Abstract available


  180. BURTSCHER J, Syed MMK, Lashuel HA, Millet GP, et al
    Hypoxia Conditioning as a Promising Therapeutic Target in Parkinson's Disease?
    Mov Disord. 2021 Feb 27. doi: 10.1002/mds.28544.
    PubMed     Abstract available


  181. MARKAKI I, Ntetsika T, Sorjonen K, Svenningsson P, et al
    Euglycemia Indicates Favorable Motor Outcome in Parkinson's Disease.
    Mov Disord. 2021 Feb 26. doi: 10.1002/mds.28545.
    PubMed     Abstract available


  182. CHAHINE LM, Zhu X, Ehrenkranz R, Chen H, et al
    Changes in Self-Reported Energy Levels in Prodromal Parkinson's Disease.
    Mov Disord. 2021 Feb 26. doi: 10.1002/mds.28535.
    PubMed    


  183. KAKAR RS, Pastor JV, Moe OW, Ambrosio F, et al
    Peripheral Klotho and Parkinson's Disease.
    Mov Disord. 2021 Feb 25. doi: 10.1002/mds.28530.
    PubMed    


  184. MOONEN AJH, Mulders AEP, Defebvre L, Duits A, et al
    Cognitive Behavioral Therapy for Anxiety in Parkinson's Disease: A Randomized Controlled Trial.
    Mov Disord. 2021 Feb 22. doi: 10.1002/mds.28533.
    PubMed     Abstract available


  185. AVENALI M, Cerri S, Ongari G, Ghezzi C, et al
    Profiling the Biochemical Signature of GBA-Related Parkinson's Disease in Peripheral Blood Mononuclear Cells.
    Mov Disord. 2021 Feb 22. doi: 10.1002/mds.28496.
    PubMed     Abstract available


  186. LIU H, Koros C, Strohaker T, Schulte C, et al
    A Novel SNCA A30G Mutation Causes Familial Parkinson's Disease.
    Mov Disord. 2021 Feb 22. doi: 10.1002/mds.28534.
    PubMed     Abstract available


  187. SONG S, Luo Z, Li C, Huang X, et al
    Changes in Body Composition Before and After Parkinson's Disease Diagnosis.
    Mov Disord. 2021 Feb 22:e28536. doi: 10.1002/mds.28536.
    PubMed     Abstract available


  188. AEED F, Cermak N, Schiller J, Schiller Y, et al
    Intrinsic Disruption of the M1 Cortical Network in a Mouse Model of Parkinson's Disease.
    Mov Disord. 2021 Feb 19. doi: 10.1002/mds.28538.
    PubMed     Abstract available


  189. KLEINER G, Fernandez HH, Chou KL, Fasano A, et al
    Non-Motor Fluctuations in Parkinson's Disease: Validation of the Non-Motor Fluctuation Assessment Questionnaire.
    Mov Disord. 2021 Feb 15. doi: 10.1002/mds.28507.
    PubMed     Abstract available


  190. GALPER J, Balwani M, Fahn S, Waters C, et al
    Cytokines and Gaucher Biomarkers in Glucocerebrosidase Carriers With and Without Parkinson Disease.
    Mov Disord. 2021 Feb 11. doi: 10.1002/mds.28525.
    PubMed     Abstract available


  191. BRIGHT JM, Carlisle HJ, Toda AMA, Murphy M, et al
    Differential Inhibition of LRRK2 in Parkinson's Disease Patient Blood by a G2019S Selective LRRK2 Inhibitor.
    Mov Disord. 2021 Feb 11. doi: 10.1002/mds.28490.
    PubMed     Abstract available


  192. PAZ RM, Tubert C, Stahl AM, Amarillo Y, et al
    Levodopa Causes Striatal Cholinergic Interneuron Burst-Pause Activity in Parkinsonian Mice.
    Mov Disord. 2021 Feb 6. doi: 10.1002/mds.28516.
    PubMed     Abstract available


  193. ANTAR T, Iwaki H, B Singleton A
    Reply to: 'Letter to the Editor on "Sex Differences in Parkinson's Disease Phenotype and Caregiving Disparities"'.
    Mov Disord. 2021;36:527-528.
    PubMed    


  194. OUTEIRO TF, Krisko A
    Reply to: "Parkinson's Disease and COVID-19: Do We Need to Be More Patient?"
    Mov Disord. 2021;36:278-279.
    PubMed    


  195. GONZALEZ-LATAPI P, Fearon C, Fasano A, Lang AE, et al
    Parkinson's Disease and COVID-19: Do We Need to Be More Patient?
    Mov Disord. 2021;36:277.
    PubMed    


  196. DE LA ROSA T, Amado Scerni D, Scorza FA
    Sex Differences in Parkinson's Disease Phenotype and Caregiving Disparities.
    Mov Disord. 2021;36:526.
    PubMed    


  197. HO GPH, Ramalingam N, Imberdis T, Wilkie EC, et al
    Upregulation of Cellular Palmitoylation Mitigates alpha-Synuclein Accumulation and Neurotoxicity.
    Mov Disord. 2021;36:348-359.
    PubMed     Abstract available


    January 2021
  198. MULLER-NEDEBOCK AC, van der Westhuizen FH, Koks S, Bardien S, et al
    Nuclear Genes Associated with Mitochondrial DNA Processes as Contributors to Parkinson's Disease Risk.
    Mov Disord. 2021 Jan 29. doi: 10.1002/mds.28475.
    PubMed     Abstract available


  199. JEONG SH, Lee HS, Jung JH, Baik K, et al
    White Matter Hyperintensities, Dopamine Loss, and Motor Deficits in De Novo Parkinson's Disease.
    Mov Disord. 2021 Jan 29. doi: 10.1002/mds.28510.
    PubMed     Abstract available



  200. GP2: The Global Parkinson's Genetics Program.
    Mov Disord. 2021 Jan 29. doi: 10.1002/mds.28494.
    PubMed    


  201. KIM JJ, Makarious MB, Bandres-Ciga S, Gibbs JR, et al
    The Parkinson's Disease DNA Variant Browser.
    Mov Disord. 2021 Jan 26. doi: 10.1002/mds.28488.
    PubMed     Abstract available


  202. MONJE MHG, Sanchez-Ferro A, Pineda-Pardo JA, Vela-Desojo L, et al
    Motor Onset Topography and Progression in Parkinson's Disease: the Upper Limb Is First.
    Mov Disord. 2021 Jan 20. doi: 10.1002/mds.28462.
    PubMed     Abstract available


  203. DONAHUE EK, Murdos A, Jakowec MW, Sheikh-Bahaei N, et al
    Global and Regional Changes in Perivascular Space in Idiopathic and Familial Parkinson's Disease.
    Mov Disord. 2021 Jan 20. doi: 10.1002/mds.28473.
    PubMed     Abstract available


  204. WELTON T, Tan EK
    Applying Artificial Intelligence to Multi-Omic Data: New Functional Variants in Parkinson's Disease.
    Mov Disord. 2021 Jan 17. doi: 10.1002/mds.28481.
    PubMed    


  205. MICHELI F, Vissani M, Pecchioli G, Terenzi F, et al
    Impulsivity Markers in Parkinsonian Subthalamic Single-Unit Activity.
    Mov Disord. 2021 Jan 16. doi: 10.1002/mds.28497.
    PubMed     Abstract available


  206. AVRAM CM, Brumbach BH, Hiller AL
    A Report of Tamoxifen and Parkinson's Disease in a US Population and a Review of the Literature.
    Mov Disord. 2021 Jan 15. doi: 10.1002/mds.28471.
    PubMed     Abstract available


  207. LIN CH, Chang CH, Tai CH, Cheng MF, et al
    A Double-Blind, Randomized, Controlled Trial of Lovastatin in Early-Stage Parkinson's Disease.
    Mov Disord. 2021 Jan 15. doi: 10.1002/mds.28474.
    PubMed     Abstract available


  208. RAVANIDIS S, Bougea A, Karampatsi D, Papagiannakis N, et al
    Differentially Expressed Circular RNAs in Peripheral Blood Mononuclear Cells of Patients with Parkinson's Disease.
    Mov Disord. 2021 Jan 12. doi: 10.1002/mds.28467.
    PubMed     Abstract available


  209. HERZ DM, Meder D, Camilleri JA, Eickhoff SB, et al
    Brain Motor Network Changes in Parkinson's Disease: Evidence from Meta-Analytic Modeling.
    Mov Disord. 2021 Jan 11. doi: 10.1002/mds.28468.
    PubMed     Abstract available


  210. VILA-VICOSA D, Clemente A, Pona-Ferreira F, Leitao M, et al
    Unsupervised walking activity assessment reveals COVID-19 impact on Parkinson's disease patients.
    Mov Disord. 2021 Jan 11. doi: 10.1002/mds.28514.
    PubMed    


  211. ZARKALI A, McColgan P, Leyland LA, Lees AJ, et al
    Visual Dysfunction Predicts Cognitive Impairment and White Matter Degeneration in Parkinson's Disease.
    Mov Disord. 2021 Jan 9. doi: 10.1002/mds.28477.
    PubMed     Abstract available


  212. KUUSIMAKI T, Al-Abdulrasul H, Kurki S, Hietala J, et al
    Increased Risk of Parkinson's Disease in Patients With Schizophrenia Spectrum Disorders.
    Mov Disord. 2021 Jan 6. doi: 10.1002/mds.28484.
    PubMed     Abstract available


  213. CHEN L, Bedard P, Hallett M, Horovitz SG, et al
    Dynamics of Top-Down Control and Motor Networks in Parkinson's Disease.
    Mov Disord. 2021 Jan 6. doi: 10.1002/mds.28461.
    PubMed     Abstract available


  214. SCHIRINZI T, Maftei D, Pieri M, Bernardini S, et al
    Increase of Prokineticin-2 in Serum of Patients with Parkinson's Disease.
    Mov Disord. 2021 Jan 6. doi: 10.1002/mds.28458.
    PubMed    


  215. METCALFE-ROACH A, Yu AC, Golz E, Cirstea M, et al
    MIND and Mediterranean Diets Associated with Later Onset of Parkinson's Disease.
    Mov Disord. 2021 Jan 6. doi: 10.1002/mds.28464.
    PubMed     Abstract available


  216. BAUMGARTNER AJ, Press DZ, Simon DK
    The Relationship Between Olfactory Dysfunction and Constipation in Early Parkinson's Disease.
    Mov Disord. 2021 Jan 6. doi: 10.1002/mds.28483.
    PubMed    


  217. CHOE CU, Potter-Nerger M, Buhmann C, Blankenberg S, et al
    Reply to: "Parkin Deficiency Appears Not to Be Associated with Cardiac Damage in Parkinson's Disease".
    Mov Disord. 2021;36:273-274.
    PubMed    


  218. TRILCK-WINKLER M, Borsche M, Konig IR, Balck A, et al
    Parkin Deficiency Appears Not to Be Associated with Cardiac Damage in Parkinson's Disease.
    Mov Disord. 2021;36:271-273.
    PubMed    


  219. WITT K
    The Impact of the Basal Ganglia on Working Memory: Evidence from Parkinson's Disease.
    Mov Disord. 2021;36:13-15.
    PubMed    


  220. FULLER RLM, Sanchez-Ferro A, Goetz CG, Martinez-Martin P, et al
    In Support of Electronic Versions of Movement Disorder Society Rating Scales.
    Mov Disord. 2021;36:270-271.
    PubMed    


  221. TURNER TH, Dale ML
    Reply to: "In Support of Electronic Versions of Movement Disorder Society Rating Scales".
    Mov Disord. 2021;36:271.
    PubMed    


  222. SARANZA G, Lang AE
    Inhaled Levodopa as a Potential Treatment for Diphasic Dyskinesia.
    Mov Disord. 2021;36:265-266.
    PubMed    


  223. KIEBURTZ K, Katz R, McGarry A, Olanow CW, et al
    A New Approach to the Development of Disease-Modifying Therapies for PD; Fighting Another Pandemic.
    Mov Disord. 2021;36:59-63.
    PubMed     Abstract available


  224. VIEIRA-YANO B, Martini DN, Horak FB, de Lima-Pardini A, et al
    The Adapted Resistance Training with Instability Randomized Controlled Trial for Gait Automaticity.
    Mov Disord. 2021;36:152-163.
    PubMed     Abstract available


    December 2020
  225. WILSON J, Yarnall AJ, Craig CE, Galna B, et al
    Cholinergic Basal Forebrain Volumes Predict Gait Decline in Parkinson's Disease.
    Mov Disord. 2020 Dec 31. doi: 10.1002/mds.28453.
    PubMed     Abstract available


  226. DUITS AA, Boots LMM, Mulders AEP, Moonen AJH, et al
    Covid Proof Self-Management Training for Caregivers of Patients with Parkinson's Disease.
    Mov Disord. 2020 Dec 27. doi: 10.1002/mds.28457.
    PubMed    


  227. FILIPPOU P, Outeiro TF
    Cancer and Parkinson's Disease: Common Targets, Emerging Hopes.
    Mov Disord. 2020 Dec 21. doi: 10.1002/mds.28425.
    PubMed     Abstract available


  228. NISSEN SK, Ferreira SA, Nielsen MC, Schulte C, et al
    Soluble CD163 Changes Indicate Monocyte Association With Cognitive Deficits in Parkinson's Disease.
    Mov Disord. 2020 Dec 17. doi: 10.1002/mds.28424.
    PubMed     Abstract available


  229. ZOON TJC, van Rooijen G, Balm GMFC, Bergfeld IO, et al
    Apathy Induced by Subthalamic Nucleus Deep Brain Stimulation in Parkinson's Disease: A Meta-Analysis.
    Mov Disord. 2020 Dec 16. doi: 10.1002/mds.28390.
    PubMed     Abstract available


  230. SKRAHINA V, Gaber H, Vollstedt EJ, Forster TM, et al
    The Rostock International Parkinson's Disease (ROPAD) Study: Protocol and Initial Findings.
    Mov Disord. 2020 Dec 14. doi: 10.1002/mds.28416.
    PubMed     Abstract available


  231. KLINE EM, Houser MC, Herrick MK, Seibler P, et al
    Genetic and Environmental Factors in Parkinson's Disease Converge on Immune Function and Inflammation.
    Mov Disord. 2020 Dec 14. doi: 10.1002/mds.28411.
    PubMed     Abstract available


  232. ELFIL M, Bahbah EI, Attia MM, Eldokmak M, et al
    Impact of Obstructive Sleep Apnea on Cognitive and Motor Functions in Parkinson's Disease.
    Mov Disord. 2020 Dec 9. doi: 10.1002/mds.28412.
    PubMed     Abstract available


  233. MULLIN S, Stokholm MG, Hughes D, Mehta A, et al
    Brain Microglial Activation Increased in Glucocerebrosidase (GBA) Mutation Carriers without Parkinson's disease.
    Mov Disord. 2020 Dec 5. doi: 10.1002/mds.28375.
    PubMed     Abstract available


  234. CAREY G, Gormezoglu M, de Jong JJA, Hofman PAM, et al
    Neuroimaging of Anxiety in Parkinson's Disease: A Systematic Review.
    Mov Disord. 2020 Dec 2. doi: 10.1002/mds.28404.
    PubMed     Abstract available


  235. OLSZEWSKA DA, Lang AE
    "Opening" New Insights Into LRRK2 Conformation and the Microtubule.
    Mov Disord. 2020;35:2162-2163.
    PubMed    


    November 2020
  236. MARTIN WRW, Miles M, Zhong Q, Hartlein J, et al
    Is Levodopa Response a Valid Indicator of Parkinson's Disease?
    Mov Disord. 2020 Nov 30. doi: 10.1002/mds.28406.
    PubMed     Abstract available


  237. GUTTLER C, Altschuler J, Tanev K, Bockmann S, et al
    Levodopa-Induced Dyskinesia Are Mediated by Cortical Gamma Oscillations in Experimental Parkinsonism.
    Mov Disord. 2020 Nov 28. doi: 10.1002/mds.28403.
    PubMed     Abstract available


  238. PORTLEY MK, Scholz SW
    Hot Topic: Epigenetics in Parkinson's Disease: A New Frontier for Disease-Modifying Therapies.
    Mov Disord. 2020 Nov 27. doi: 10.1002/mds.28410.
    PubMed    


  239. SANTOS-GARCIA D, Pozojevic J, de Deus Fonticoba T, Kurtis M, et al
    First Case of Parkinsonian-Pyramidal Syndrome Associated with a TBK1 Mutation.
    Mov Disord. 2020 Nov 27. doi: 10.1002/mds.28405.
    PubMed    


  240. WALDTHALER J, Stock L, Sommerkorn J, Kruger-Zechlin C, et al
    Antisaccade Latency Is Sensitive to Longitudinal Change of Motor and Cognitive Symptoms in Parkinson's Disease.
    Mov Disord. 2020 Nov 25. doi: 10.1002/mds.28374.
    PubMed    


  241. AL-QASSABI A, Tsao TS, Racolta A, Kremer T, et al
    Immunohistochemical Detection of Synuclein Pathology in Skin in Idiopathic Rapid Eye Movement Sleep Behavior Disorder and Parkinsonism.
    Mov Disord. 2020 Nov 24. doi: 10.1002/mds.28399.
    PubMed     Abstract available


  242. JAAKKOLA E, Huovinen A, Kaasinen V, Joutsa J, et al
    No Change in Prevalence of Impulse Control Disorder Behaviors in Parkinson's Disease During the Last Decade.
    Mov Disord. 2020 Nov 24. doi: 10.1002/mds.28400.
    PubMed    


  243. GARCIA-SANZ P, M F G Aerts J, Moratalla R
    The Role of Cholesterol in alpha-Synuclein and Lewy Body Pathology in GBA1 Parkinson's Disease.
    Mov Disord. 2020 Nov 21. doi: 10.1002/mds.28396.
    PubMed     Abstract available


  244. PAGAN FL, Wilmarth B, Torres-Yaghi Y, Hebron ML, et al
    Long-Term Safety and Clinical Effects of Nilotinib in Parkinson's Disease.
    Mov Disord. 2020 Nov 20. doi: 10.1002/mds.28389.
    PubMed     Abstract available


  245. ERREA O, Rodriguez-Oroz MC
    Oligodendrocytes, a New Player in the Etiology of Parkinson's Disease.
    Mov Disord. 2020 Nov 18. doi: 10.1002/mds.28393.
    PubMed    


  246. OJUKWU DI, Andruska KM, Halpern CH
    Lessons From George Floyd: Racial Inequalities in the Treatment of Parkinson's Disease.
    Mov Disord. 2020 Nov 17. doi: 10.1002/mds.28388.
    PubMed    


  247. ISHIBASHI K, Miura Y, Wagatsuma K, Toyohara J, et al
    Adenosine A2A Receptor Occupancy by Long-Term Istradefylline Administration in Parkinson's Disease.
    Mov Disord. 2020 Nov 16. doi: 10.1002/mds.28378.
    PubMed    


  248. OUTEIRO TF, Heutink P, Bezard E, Cenci AM, et al
    From iPS Cells to Rodents and Nonhuman Primates: Filling Gaps in Modeling Parkinson's Disease.
    Mov Disord. 2020 Nov 16. doi: 10.1002/mds.28387.
    PubMed     Abstract available


  249. VIGNATELLI L, Zenesini C, Belotti LMB, Baldin E, et al
    Risk of hospitalization and death for COVID-19 in people with Parkinson's disease or parkinsonism.
    Mov Disord. 2020 Nov 16. doi: 10.1002/mds.28408.
    PubMed     Abstract available


  250. MAETZLER W, Rochester L, Bhidayasiri R, Espay AJ, et al
    Modernizing Daily Function Assessment in Parkinson's Disease Using Capacity, Perception, and Performance Measures.
    Mov Disord. 2020 Nov 15. doi: 10.1002/mds.28377.
    PubMed     Abstract available


  251. DEVOS D, Hirsch E, Wyse R
    Seven Solutions for Neuroprotection in Parkinson's Disease.
    Mov Disord. 2020 Nov 13. doi: 10.1002/mds.28379.
    PubMed     Abstract available


  252. DE MICCO R, Satolli S, Siciliano M, Di Nardo F, et al
    Connectivity Correlates of Anxiety Symptoms in Drug-Naive Parkinson's Disease Patients.
    Mov Disord. 2020 Nov 10. doi: 10.1002/mds.28372.
    PubMed     Abstract available


  253. PICILLO M, Phokaewvarangkul O, Poon YY, McIntyre CC, et al
    Levodopa Versus Dopamine Agonist After Subthalamic Stimulation in Parkinson's Disease.
    Mov Disord. 2020 Nov 9. doi: 10.1002/mds.28382.
    PubMed     Abstract available


  254. QUATTRONE A, Antonini A, Vaillancourt DE, Seppi K, et al
    A New MRI Measure to Early Differentiate Progressive Supranuclear Palsy From De Novo Parkinson's Disease in Clinical Practice: An International Study.
    Mov Disord. 2020 Nov 5. doi: 10.1002/mds.28364.
    PubMed     Abstract available


  255. SARIHAN EI, Perez-Palma E, Niestroj LM, Loesch D, et al
    Genome-Wide Analysis of Copy Number Variation in Latin American Parkinson's Disease Patients.
    Mov Disord. 2020 Nov 5. doi: 10.1002/mds.28353.
    PubMed     Abstract available


  256. VAN DER ZEE S, Muller MLTM, Kanel P, van Laar T, et al
    Cholinergic Denervation Patterns Across Cognitive Domains in Parkinson's Disease.
    Mov Disord. 2020 Nov 2. doi: 10.1002/mds.28360.
    PubMed     Abstract available


  257. CHOUGAR L, Faouzi J, Pyatigorskaya N, Yahia-Cherif L, et al
    Automated Categorization of Parkinsonian Syndromes Using Magnetic Resonance Imaging in a Clinical Setting.
    Mov Disord. 2020 Nov 2. doi: 10.1002/mds.28348.
    PubMed     Abstract available


  258. DORSEY ER, Bloem BR, Okun MS
    A New Day: The Role of Telemedicine in Reshaping Care for Persons With Movement Disorders.
    Mov Disord. 2020;35:1897-1902.
    PubMed     Abstract available


  259. HERRINGTON TM, Schweitzer J, Henchcliffe C, Carter BS, et al
    Toward a Personalized Approach to Parkinson's Cell Therapy.
    Mov Disord. 2020;35:2119-2120.
    PubMed    


  260. SILVA-BATISTA C, M Corcos D, B Horak F, Ugrinowitsch C, et al
    Reply to: 'Letter to the Editor on "A Randomized Controlled Trial of Exercise for Parkinsonian Individuals With Freezing of Gait"'.
    Mov Disord. 2020;35:2123-2124.
    PubMed    


  261. KORDOWER JH, Okun MS, Jankovic J
    Reply to: "Toward a Personalized Approach to Parkinson's Cell Therapy".
    Mov Disord. 2020;35:2120-2121.
    PubMed    


  262. NONNEKES J, Gilat M, D'Cruz N, Dijkstra BW, et al
    Letter to the Editor on "A Randomized, Controlled Trial of Exercise for Parkinsonian Individuals With Freezing of Gait".
    Mov Disord. 2020;35:2122-2123.
    PubMed    


    October 2020
  263. TAN MMX, Lawton MA, Jabbari E, Reynolds RH, et al
    Genome-Wide Association Studies of Cognitive and Motor Progression in Parkinson's Disease.
    Mov Disord. 2020 Oct 28. doi: 10.1002/mds.28342.
    PubMed     Abstract available


  264. SUN YM, Yu HL, Zhou XY, Xiong WX, et al
    Disease Progression in Patients with Parkin-Related Parkinson's Disease in a Longitudinal Cohort.
    Mov Disord. 2020 Oct 27. doi: 10.1002/mds.28349.
    PubMed     Abstract available


  265. MENOZZI E, Macnaughtan J, Schapira AHV
    LRRK2 Parkinsonism: Does the Response to Gut Bacteria Mitigate the Neurological Picture?
    Mov Disord. 2020 Oct 27. doi: 10.1002/mds.28347.
    PubMed    


  266. VAN DEN HEUVEL L, Evers L, Meinders M, Post B, et al
    Estimating the Effect of Early Treatment Initiation in Parkinson's Disease Using Observational Data.
    Mov Disord. 2020 Oct 27. doi: 10.1002/mds.28339.
    PubMed     Abstract available


  267. BEYLERGIL SB, Petersen M, Gupta P, Elkasaby M, et al
    Severity-Dependent Effects of Parkinson's Disease on Perception of Visual and Vestibular Heading.
    Mov Disord. 2020 Oct 26. doi: 10.1002/mds.28352.
    PubMed     Abstract available


  268. YE Z, Zhang G, Zhang Y, Li S, et al
    The Role of the Subthalamic Nucleus in Sequential Working Memory in De Novo Parkinson's Disease.
    Mov Disord. 2020 Oct 24. doi: 10.1002/mds.28344.
    PubMed     Abstract available


  269. VAN DER HEIDE A, Meinders MJ, Speckens AEM, Peerbolte TF, et al
    Stress and Mindfulness in Parkinson's Disease: Clinical Effects and Potential Underlying Mechanisms.
    Mov Disord. 2020 Oct 23. doi: 10.1002/mds.28345.
    PubMed     Abstract available


  270. FU JF, Matarazzo M, McKenzie J, Neilson N, et al
    Serotonergic System Impacts Levodopa Response in Early Parkinson's and Future Risk of Dyskinesia.
    Mov Disord. 2020 Oct 22. doi: 10.1002/mds.28340.
    PubMed     Abstract available


  271. YIN W, Lof M, Pedersen NL, Sandin S, et al
    Mediterranean Dietary Pattern at Middle Age and Risk of Parkinson's Disease: A Swedish Cohort Study.
    Mov Disord. 2020 Oct 20. doi: 10.1002/mds.28314.
    PubMed     Abstract available


  272. TAKEDA A, Takahashi R, Tsuboi Y, Nomoto M, et al
    Randomized, Controlled Study of Opicapone in Japanese Parkinson's Patients With Motor Fluctuations.
    Mov Disord. 2020 Oct 19. doi: 10.1002/mds.28322.
    PubMed     Abstract available


  273. LOWES H, Robertson F, Pyle A, Hussain R, et al
    The human coronavirus receptor ANPEP (CD13) is overexpressed in Parkinson's disease.
    Mov Disord. 2020 Oct 18. doi: 10.1002/mds.28354.
    PubMed    


  274. SCHLOSSMACHER MG, Graybiel AM
    Conversations With Dr. Oleh Hornykiewicz, Founding Father of the Dopamine Era in Parkinson's: How Do You Wish to Be Remembered?
    Mov Disord. 2020 Oct 14. doi: 10.1002/mds.28316.
    PubMed     Abstract available


  275. TAKAMIYA A, Seki M, Kudo S, Yoshizaki T, et al
    Electroconvulsive Therapy for Parkinson's Disease: A Systematic Review and Meta-Analysis.
    Mov Disord. 2020 Oct 14. doi: 10.1002/mds.28335.
    PubMed     Abstract available


  276. MESTRE TA, Kessler D, Cote D, Liddy C, et al
    Pilot Evaluation of a Pragmatic Network for Integrated Care and Self-Management in Parkinson's Disease.
    Mov Disord. 2020 Oct 14. doi: 10.1002/mds.28332.
    PubMed     Abstract available


  277. BELVISI D, Fabbrini A, De Bartolo MI, Costanzo M, et al
    The Pathophysiological Correlates of Parkinson's Disease Clinical Subtypes.
    Mov Disord. 2020 Oct 10. doi: 10.1002/mds.28321.
    PubMed     Abstract available


  278. DAHODWALA N, Li P, Jahnke J, Ladage VP, et al
    Burden of Parkinson's Disease by Severity: Health Care Costs in the U.S. Medicare Population.
    Mov Disord. 2020 Oct 8. doi: 10.1002/mds.28265.
    PubMed     Abstract available


  279. SANTIN MDN, Voulleminot P, Vrillon A, Hainque E, et al
    Impact of Subthalamic Deep Brain Stimulation on Impulse Control Disorders in Parkinson's Disease: A Prospective Study.
    Mov Disord. 2020 Oct 6. doi: 10.1002/mds.28320.
    PubMed     Abstract available


  280. ISRAEL Z, Asch N
    Reversing a Model of Parkinson's Disease With In Situ Converted Nigral Neurons.
    Mov Disord. 2020 Oct 5. doi: 10.1002/mds.28306.
    PubMed    


  281. BONVEGNA S, Straccia G, Golfre Andreasi N, Elia AE, et al
    Parkinsonism and Nigrostriatal Damage Secondary to CSF1R-Related Primary Microgliopathy.
    Mov Disord. 2020 Oct 3. doi: 10.1002/mds.28290.
    PubMed    


  282. KANE PB, Benjamin DM, Barker RA, Lang AE, et al
    Comparison of Patient and Expert Perceptions of the Attainment of Research Milestones in Parkinson's Disease.
    Mov Disord. 2020 Oct 1. doi: 10.1002/mds.28319.
    PubMed     Abstract available


  283. TSUBOI T, Charbel M, Peterside DT, Rana M, et al
    Pallidal Connectivity Profiling of Stimulation-Induced Dyskinesia in Parkinson's Disease.
    Mov Disord. 2020 Oct 1. doi: 10.1002/mds.28324.
    PubMed     Abstract available


  284. IWAKI H, Blauwendraat C, Leonard HL, Makarious MB, et al
    Differences in the Presentation and Progression of Parkinson's Disease by Sex.
    Mov Disord. 2020 Oct 1. doi: 10.1002/mds.28312.
    PubMed     Abstract available


  285. MUFTI K, Rudakou U, Yu E, Krohn L, et al
    Comprehensive Analysis of Familial Parkinsonism Genes in Rapid-Eye-Movement Sleep Behavior Disorder.
    Mov Disord. 2020 Oct 1. doi: 10.1002/mds.28318.
    PubMed     Abstract available


  286. ACHBANI A, Sine H, Naciri A, Baba MA, et al
    Reply to: "Can the 2019 Novel Coronavirus Cause Parkinson's Disease?"
    Mov Disord. 2020;35:1726.
    PubMed    


  287. HURWITZ B, Lees AJ, Walusinski O
    Light and Shade in Patrick Lewis et al's Paper on the First Photographs of Parkinson's Disease.
    Mov Disord. 2020;35:1880-1881.
    PubMed    


  288. SULLIVAN R, Yau WY, Chelban V, Rossi S, et al
    Dopa-Responsive Parkinsonism in a Patient With Homozygous RFC1 Expansions.
    Mov Disord. 2020;35:1890-1891.
    PubMed    


  289. DA SILVA SCHMITT G, Martinez ARM, da Graca FF, de Lima FD, et al
    Dopa-Responsive Parkinsonism in a Patient With Homozygous RFC1 Expansions.
    Mov Disord. 2020;35:1889-1890.
    PubMed    


  290. AGUIRRE-PADILLA DH, Lozano AM, Fasano A
    Reply to: "Spinal Cord Stimulation for Parkinson's Disease: Dynamic Habituation as a Mechanism of Failure?"
    Mov Disord. 2020;35:1883.
    PubMed    


  291. MONTGOMERY EB JR
    Debugging Adaptive Deep Brain Stimulation for Parkinson's Disease.
    Mov Disord. 2020;35:1891.
    PubMed    


  292. CURY RG, Carra RB, Capato TTC, Teixeira MJ, et al
    Spinal Cord Stimulation for Parkinson's Disease: Dynamic Habituation as a Mechanism of Failure?
    Mov Disord. 2020;35:1882-1883.
    PubMed    


  293. MONJE MHG, Martinez-Fernandez R
    Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Parkinsonism: Is There Evidence for Concern?
    Mov Disord. 2020;35:1725.
    PubMed    


  294. ALVES M, Caldeira D, Reimao S, Ferro JM, et al
    N-Terminal Pro-B-Type Natriuretic Peptide Levels in Parkinson's Disease.
    Mov Disord. 2020;35:1886-1887.
    PubMed    


  295. CHOE CU, Petersen E, Potter-Nerger M, Buhmann C, et al
    Reply to: "N-Terminal Pro-B-Type Natriuretic Peptide Levels in Parkinson's Disease".
    Mov Disord. 2020;35:1888.
    PubMed    


  296. LEWIS PA, Plun-Favreau H, Rowley M, Spillane J, et al
    Reply to: "Light and Shade in Patrick Lewis et al's Paper on the First Photographs of Parkinson's Disease".
    Mov Disord. 2020;35:1882.
    PubMed    


  297. CROTTY GF, Lo RY, Schwarzschild MA
    If LRRK2 Set the Fire, Can Nonsteroidal Anti-inflammatory Drugs Wet the Flames?
    Mov Disord. 2020;35:1727-1730.
    PubMed    


    September 2020
  298. BLUMENREICH S, Jenkins BJ, Barav OB, Milenkovic I, et al
    The Lysosome and Nonmotor Symptoms: Linking Parkinson's Disease and Lysosomal Storage Disorders.
    Mov Disord. 2020 Sep 28. doi: 10.1002/mds.28232.
    PubMed    


  299. RAJPUT AH, Kish SJ
    Professor Oleh Hornykiewicz, MD (1926-2020): Remembering the Father of the Modern Treatment of Parkinson's Disease and the Man.
    Mov Disord. 2020 Sep 28. doi: 10.1002/mds.28317.
    PubMed    


  300. AL ALI J, Vaine CA, Shah S, Campion L, et al
    TAF1 Transcripts and Neurofilament Light Chain as Biomarkers for X-Linked Dystonia-Parkinsonism.
    Mov Disord. 2020 Sep 25. doi: 10.1002/mds.28305.
    PubMed     Abstract available


  301. YU E, Rudakou U, Krohn L, Mufti K, et al
    Analysis of Heterozygous PRKN Variants and Copy-Number Variations in Parkinson's Disease.
    Mov Disord. 2020 Sep 24. doi: 10.1002/mds.28299.
    PubMed     Abstract available


  302. DOMMERSHUIJSEN LJ, Heshmatollah A, Mattace Raso FUS, Koudstaal PJ, et al
    Orthostatic Hypotension: A Prodromal Marker of Parkinson's Disease?
    Mov Disord. 2020 Sep 23. doi: 10.1002/mds.28303.
    PubMed     Abstract available


  303. MANNE S, Kondru N, Jin H, Serrano GE, et al
    Blinded RT-QuIC Analysis of alpha-Synuclein Biomarker in Skin Tissue from Parkinson's Disease Patients.
    Mov Disord. 2020 Sep 22. doi: 10.1002/mds.28242.
    PubMed     Abstract available


  304. DIAW SH, Lohmann K
    Linking Huntington's Disease and X-Linked Dystonia Parkinsonism on the Molecular Level.
    Mov Disord. 2020 Sep 22. doi: 10.1002/mds.28287.
    PubMed    


  305. TERROBA-CHAMBI C, Abulafia C, Vigo DE, Merello M, et al
    Heart Rate Variability and Mild Cognitive Impairment in Parkinson's Disease.
    Mov Disord. 2020 Sep 21. doi: 10.1002/mds.28234.
    PubMed    


  306. ZHANG Q, Schultz JL, Aldridge GM, Simmering JE, et al
    COVID-19 case fatality and Parkinson's disease.
    Mov Disord. 2020 Sep 21. doi: 10.1002/mds.28325.
    PubMed    


  307. PAULY MG, Ruiz Lopez M, Westenberger A, Saranza G, et al
    Expanding Data Collection for the MDSGene Database: X-Linked Dystonia-Parkinsonism as Use Case Example.
    Mov Disord. 2020 Sep 19. doi: 10.1002/mds.28289.
    PubMed     Abstract available


  308. FLORIN E, Koschmieder KC, Schnitzler A, Becker S, et al
    Recovery of Impaired Endogenous Pain Modulation by Dopaminergic Medication in Parkinson's Disease.
    Mov Disord. 2020 Sep 18. doi: 10.1002/mds.28241.
    PubMed     Abstract available


  309. KRISMER F, Beliveau V, Seppi K, Mueller C, et al
    Automated Analysis of Diffusion-Weighted Magnetic Resonance Imaging for the Differential Diagnosis of Multiple System Atrophy from Parkinson's Disease.
    Mov Disord. 2020 Sep 16. doi: 10.1002/mds.28281.
    PubMed     Abstract available


  310. JUNG JH, Kim BH, Chung SJ, Yoo HS, et al
    Motor Cerebellar Connectivity and Future Development of Freezing of Gait in De Novo Parkinson's Disease.
    Mov Disord. 2020 Sep 14. doi: 10.1002/mds.28243.
    PubMed     Abstract available


  311. TANTAWY AAG, Adly AAM, Hashem NH, Ebeid WM, et al
    Ganglion Cell Complex Thinning in Young Gaucher Patients: Relation to Prodromal Parkinsonian Markers.
    Mov Disord. 2020 Sep 12. doi: 10.1002/mds.28256.
    PubMed     Abstract available


  312. PERINAN MT, Macias-Garcia D, Labrador-Espinosa MA, Jesus S, et al
    Association of PICALM with Cognitive Impairment in Parkinson's Disease.
    Mov Disord. 2020 Sep 11. doi: 10.1002/mds.28283.
    PubMed     Abstract available


  313. REIMAO S, Guerreiro C, Seppi K, Ferreira JJ, et al
    A Standardized MR Imaging Protocol for Parkinsonism.
    Mov Disord. 2020 Sep 11. doi: 10.1002/mds.28204.
    PubMed    


  314. KOGAN RV, Janzen A, Meles SK, Sittig E, et al
    Four-Year Follow-up of [(18) F]Fluorodeoxyglucose Positron Emission Tomography-Based Parkinson's Disease-Related Pattern Expression in 20 Patients With Isolated Rapid Eye Movement Sleep Behavior Disorder Shows Prodromal Progression.
    Mov Disord. 2020 Sep 10. doi: 10.1002/mds.28260.
    PubMed     Abstract available


  315. KRAUSE C, Schaake S, Grutz K, Sievert H, et al
    DNA Methylation as a Potential Molecular Mechanism in X-Linked Dystonia-Parkinsonism.
    Mov Disord. 2020 Sep 10. doi: 10.1002/mds.28239.
    PubMed     Abstract available


  316. LI C, Ou R, Chen Y, Gu X, et al
    ATP10B and the Risk for Early-Onset Parkinson's Disease.
    Mov Disord. 2020 Sep 9. doi: 10.1002/mds.28285.
    PubMed    


  317. MELLO LGM, Bissoli LB, Saraiva FP, Maia RPD, et al
    Retinal Layers and Choroid Measurements in Parkinson's Disease with or Without Pramipexole Treatment.
    Mov Disord. 2020 Sep 9. doi: 10.1002/mds.28280.
    PubMed    


  318. TAN AH, Lim SY, Mahadeva S, Loke MF, et al
    Helicobacter pylori Eradication in Parkinson's Disease: A Randomized Placebo-Controlled Trial.
    Mov Disord. 2020 Sep 7. doi: 10.1002/mds.28248.
    PubMed     Abstract available


  319. FILIPPI M, Canu E, Donzuso G, Stojkovic T, et al
    Tracking Cortical Changes Throughout Cognitive Decline in Parkinson's Disease.
    Mov Disord. 2020 Sep 4. doi: 10.1002/mds.28228.
    PubMed     Abstract available


  320. SIPILA JOT, Kaasinen V
    No Change in the Age-Adjusted Incidence of Parkinson's Disease in Finland for More Than 25 Years.
    Mov Disord. 2020 Sep 2. doi: 10.1002/mds.28250.
    PubMed    


  321. CHEN SJ, Kuo CH, Kuo HC, Chen CC, et al
    The Gut Metabolite Trimethylamine N-Oxide Is Associated With Parkinson's Disease Severity and Progression.
    Mov Disord. 2020 Sep 2. doi: 10.1002/mds.28246.
    PubMed    


  322. ZHANG X
    Comment on "Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease".
    Mov Disord. 2020;35:1695.
    PubMed    


  323. LU C, Amundsen Huffmaster SL, Louie KH, Sovell-Brown K, et al
    Pallidal Oscillation Dynamics Following Cessation of Deep Brain Stimulation in Parkinson's Disease.
    Mov Disord. 2020;35:1697-1698.
    PubMed    


  324. SPEECKAERT MM, Speeckaert R, Delanghe JR
    Standardized 25-Hydroxyvitamin D Measurements in Parkinson's Disease Patients With COVID-19.
    Mov Disord. 2020;35:1497.
    PubMed    


  325. CIRSTEA MS, Yu AC, Golz E, Sundvick K, et al
    Reply to: 'Comment on "Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease"'.
    Mov Disord. 2020;35:1695-1697.
    PubMed    


  326. NEUMANN WJ, Feldmann L, Kuhn AA
    Reply to: Pallidal Low-Frequency Activity in Dystonia and Subthalamic Beta Activity in Parkinson's Disease.
    Mov Disord. 2020;35:1699.
    PubMed    


  327. CEREDA E, Fasano A, Pezzoli G
    Reply to: Standardized 25-Hydroxyvitamin D Measurements in Parkinson's Disease Patients With COVID-19.
    Mov Disord. 2020;35:1498.
    PubMed    


  328. WEIL RS
    Visual Dysfunction and Parkinson's Disease.
    Mov Disord. 2020;35:1499-1501.
    PubMed    


    August 2020
  329. SGAMBATO V
    Blood Flow as a Route for Bidirectional Propagation of Synucleinopathy in Parkinson's Disease?
    Mov Disord. 2020 Aug 31. doi: 10.1002/mds.28236.
    PubMed    


  330. GRENN FP, Kim JJ, Makarious MB, Iwaki H, et al
    The Parkinson's Disease Genome-Wide Association Study Locus Browser.
    Mov Disord. 2020 Aug 31. doi: 10.1002/mds.28197.
    PubMed     Abstract available


  331. CHEONG JLY, Goh ZHK, Marras C, Tanner CM, et al
    The impact of COVID-19 on access to Parkinson's disease medication.
    Mov Disord. 2020 Aug 28. doi: 10.1002/mds.28293.
    PubMed     Abstract available


  332. GREUEL A, Trezzi JP, Glaab E, Ruppert MC, et al
    GBA Variants in Parkinson's Disease: Clinical, Metabolomic, and Multimodal Neuroimaging Phenotypes.
    Mov Disord. 2020 Aug 27. doi: 10.1002/mds.28225.
    PubMed     Abstract available


  333. STUART S, Morris R, Giritharan A, Quinn J, et al
    Prefrontal Cortex Activity and Gait in Parkinson's Disease With Cholinergic and Dopaminergic Therapy.
    Mov Disord. 2020 Aug 24. doi: 10.1002/mds.28214.
    PubMed     Abstract available


  334. FOLLMER C
    Gut Microbiome Imbalance and Neuroinflammation: Impact of COVID-19 on Parkinson's Disease.
    Mov Disord. 2020 Aug 21. doi: 10.1002/mds.28231.
    PubMed    


  335. OLANOW CW, Calabresi P, Obeso JA
    Continuous Dopaminergic Stimulation as a Treatment for Parkinson's Disease: Current Status and Future Opportunities.
    Mov Disord. 2020 Aug 20. doi: 10.1002/mds.28215.
    PubMed     Abstract available


  336. FABER I, Brandao PRP, Menegatti F, Bispo DDC, et al
    Covid-19 and Parkinsonism: A non-post-encephalitic case.
    Mov Disord. 2020 Aug 19. doi: 10.1002/mds.28277.
    PubMed    


  337. MOLLENHAUER B, Dakna M, Kruse N, Galasko D, et al
    Validation of Serum Neurofilament Light Chain as a Biomarker of Parkinson's Disease Progression.
    Mov Disord. 2020 Aug 15. doi: 10.1002/mds.28206.
    PubMed     Abstract available


  338. MARKAKI I, Bergstrom S, Tsitsi P, Remnestal J, et al
    Cerebrospinal Fluid Levels of Kininogen-1 Indicate Early Cognitive Impairment in Parkinson's Disease.
    Mov Disord. 2020 Aug 15. doi: 10.1002/mds.28192.
    PubMed     Abstract available


  339. PALERMO G, Tommasini L, Baldacci F, Del Prete E, et al
    Impact of COVID-19 pandemic on cognition in Parkinson's disease.
    Mov Disord. 2020 Aug 10. doi: 10.1002/mds.28254.
    PubMed    


  340. SANTOS GARCIA D, Oreiro M, Perez P, Fanjul G, et al
    Impact of COVID-19 Pandemic on Parkinson s Disease: A Cross-sectional Survey of 568 Spanish Patients.
    Mov Disord. 2020 Aug 10. doi: 10.1002/mds.28261.
    PubMed     Abstract available


  341. DELVA A, Van Weehaeghe D, Koole M, Van Laere K, et al
    Loss of Presynaptic Terminal Integrity in the Substantia Nigra in Early Parkinson's Disease.
    Mov Disord. 2020 Aug 7. doi: 10.1002/mds.28216.
    PubMed     Abstract available


  342. BALESTRINO R, Tunesi S, Tesei S, Lopiano L, et al
    Penetrance of Glucocerebrosidase (GBA) Mutations in Parkinson's Disease: a Kin Cohort Study.
    Mov Disord. 2020 Aug 7. doi: 10.1002/mds.28200.
    PubMed     Abstract available


  343. CHOI JH, Lee JY, Cho JW, Koh SB, et al
    Double-Blind, Randomized, Placebo-Controlled Trial of DA-9701 in Parkinson's Disease: PASS-GI Study.
    Mov Disord. 2020 Aug 6. doi: 10.1002/mds.28219.
    PubMed     Abstract available


  344. DELLI PIZZI S, Franciotti R, Ferretti A, Edden RAE, et al
    High gamma-Aminobutyric Acid Content within the Medial Prefrontal Cortex Is a Functional Signature of Somatic Symptoms Disorder in Patients with Parkinson's Disease.
    Mov Disord. 2020 Aug 3. doi: 10.1002/mds.28221.
    PubMed     Abstract available


  345. ANTONINI A, Leta V, Teo J, Ray Chaudhuri K, et al
    Reply to: "Concerns Raised by Publication of Antonini et al., 'Outcome of Parkinson Disease Patients Affected by Covid-19'".
    Mov Disord. 2020;35:1298.
    PubMed    


  346. RAPHAEL KG
    Concerns Raised by Publication of Antonini et al., "Outcome of Parkinson Disease Patients Affected by Covid-19".
    Mov Disord. 2020;35:1297.
    PubMed    


    July 2020
  347. WEINTRAUB D, Chiang C, Kim HM, Wilkinson J, et al
    Clinical Follow-up of Parkinson's Disease With Newly Prescribed Quetiapine.
    Mov Disord. 2020 Jul 29. doi: 10.1002/mds.28193.
    PubMed    


  348. BHARAT V, Wang X
    Precision Neurology for Parkinson's Disease: Coupling Miro1-Based Diagnosis with Drug Discovery.
    Mov Disord. 2020 Jul 25. doi: 10.1002/mds.28194.
    PubMed     Abstract available


  349. HEILMAN PL, Wang EW, Lewis MM, Krzyzanowski S, et al
    Tryptophan Metabolites Are Associated With Symptoms and Nigral Pathology in Parkinson's Disease.
    Mov Disord. 2020 Jul 25. doi: 10.1002/mds.28202.
    PubMed     Abstract available


  350. HAN G, Han J, Han K, Youn J, et al
    Visual Acuity and Development of Parkinson's Disease: A Nationwide Cohort Study.
    Mov Disord. 2020 Jul 25. doi: 10.1002/mds.28184.
    PubMed     Abstract available


  351. CHEN Y, Gu X, Ou R, Zhang L, et al
    Evaluating the Role of SNCA, LRRK2, and GBA in Chinese Patients With Early-Onset Parkinson's Disease.
    Mov Disord. 2020 Jul 16. doi: 10.1002/mds.28191.
    PubMed     Abstract available


  352. LI C, Ou R, Chen Y, Gu X, et al
    Mutation Analysis of DNAJC Family for Early-Onset Parkinson's Disease in a Chinese Cohort.
    Mov Disord. 2020 Jul 14. doi: 10.1002/mds.28203.
    PubMed     Abstract available


  353. SAN LUCIANO M, Tanner CM, Meng C, Marras C, et al
    Nonsteroidal Anti-Inflammatory Use and LRRK2 Parkinson's Disease Penetrance.
    Mov Disord. 2020 Jul 14. doi: 10.1002/mds.28189.
    PubMed     Abstract available


  354. HAMEDANI AG, Abraham DS, Maguire MG, Willis AW, et al
    Visual Impairment Is More Common in Parkinson's Disease and Is a Risk Factor for Poor Health Outcomes.
    Mov Disord. 2020 Jul 14. doi: 10.1002/mds.28182.
    PubMed     Abstract available


  355. PETRUCCI S, Ginevrino M, Trezzi I, Monfrini E, et al
    GBA-Related Parkinson's Disease: Dissection of Genotype-Phenotype Correlates in a Large Italian Cohort.
    Mov Disord. 2020 Jul 13. doi: 10.1002/mds.28195.
    PubMed     Abstract available


  356. MESTRE TA, Freitas E, Basndwah A, Lopez MR, et al
    Glycopyrrolate Improves Disability from Sialorrhea in Parkinson's Disease: A 12-Week Controlled Trial.
    Mov Disord. 2020 Jul 13. doi: 10.1002/mds.28196.
    PubMed     Abstract available


  357. KLATT-SCHREINER K, Valek L, Kang JS, Khlebtovsky A, et al
    High Glucosylceramides and Low Anandamide Contribute to Sensory Loss and Pain in Parkinson's Disease.
    Mov Disord. 2020 Jul 11. doi: 10.1002/mds.28186.
    PubMed     Abstract available


  358. DE FRANCESCO E, Terzaghi M, Storelli E, Magistrelli L, et al
    CD4+ T-Cell Transcription Factors in Idiopathic REM Sleep Behavior Disorder and Parkinson's Disease.
    Mov Disord. 2020 Jul 10. doi: 10.1002/mds.28137.
    PubMed     Abstract available


  359. YING AF, Khan S, Wu Y, Jin A, et al
    Dietary Antioxidants and Risk of Parkinson's Disease in the Singapore Chinese Health Study.
    Mov Disord. 2020 Jul 9. doi: 10.1002/mds.28173.
    PubMed     Abstract available


  360. PARKER JE, Martinez A, Deutsch GK, Prabhakar V, et al
    Safety of Plasma Infusions in Parkinson's Disease.
    Mov Disord. 2020 Jul 7. doi: 10.1002/mds.28198.
    PubMed     Abstract available


  361. DEN HEIJER JM, Cullen VC, Quadri M, Schmitz A, et al
    A Large-Scale Full GBA1 Gene Screening in Parkinson's Disease in the Netherlands.
    Mov Disord. 2020 Jul 2. doi: 10.1002/mds.28112.
    PubMed     Abstract available


  362. ZETTERBERG H
    Is There a Value of Neurofilament Light as a Biomarker for Neurodegeneration in Parkinson's Disease?
    Mov Disord. 2020;35:1111-1112.
    PubMed    


  363. MACASKILL MR, Myall DJ, Shoorangiz R, Anderson TJ, et al
    Childbirth and Delayed Parkinson's Onset: A Reproducible Nonbiological Artifact of Societal Change.
    Mov Disord. 2020;35:1268-1271.
    PubMed     Abstract available


  364. CERRONI R, Pierantozzi M, Moleti A, Stefani A, et al
    Laterality of Auditory Dysfunction in Parkinson's Disease.
    Mov Disord. 2020;35:1283-1284.
    PubMed    


  365. POPAT RA, Nelson LM
    What Matters in Parkinson's Disease: Sex, Number of Children, or Birth Cohort?
    Mov Disord. 2020;35:1108-1110.
    PubMed    


  366. FRANGE C, Huebra Pimentel Filho L, Aguilar AC, Coelho FMS, et al
    Exercise for "Sleep Rehabilitation" in Parkinson's Disease.
    Mov Disord. 2020;35:1285.
    PubMed    


  367. AMARA AW, Wood KH, Joop A, Memon RA, et al
    Reply to: Exercise for "Sleep Rehabilitation" in Parkinson's Disease.
    Mov Disord. 2020;35:1286.
    PubMed    


  368. JAFARI Z, Kolb BE, Mohajerani MH
    Reply to a Letter by Dr. Stefani and Colleagues on: "Auditory Dysfunction in Parkinson's Disease".
    Mov Disord. 2020;35:1284-1285.
    PubMed    


  369. LERCHE S, Wurster I, Roben B, Zimmermann M, et al
    CSF NFL in a Longitudinally Assessed PD Cohort: Age Effects and Cognitive Trajectories.
    Mov Disord. 2020;35:1138-1144.
    PubMed     Abstract available


    June 2020
  370. AZIZ NA, Roos RAC, Pijl H
    Insulin Sensitivity in De Novo Parkinson's Disease: A Hyperinsulinemic-Euglycemic Clamp Study.
    Mov Disord. 2020 Jun 30. doi: 10.1002/mds.28181.
    PubMed    


  371. RAJAN R, Brennan L, Bloem BR, Dahodwala N, et al
    Integrated Care in Parkinson's Disease: A Systematic Review and Meta-Analysis.
    Mov Disord. 2020 Jun 29. doi: 10.1002/mds.28097.
    PubMed     Abstract available


  372. KOBYLECKI C, Jones T, Lim CK, Miller C, et al
    Phenomenology and outcomes of in-patients with Parkinson's disease during COVID-19 pandemic.
    Mov Disord. 2020 Jun 24. doi: 10.1002/mds.28205.
    PubMed    


  373. RAMIREZ J, Dilliott AA, Binns MA, Breen DP, et al
    Parkinson's Disease, NOTCH3 Genetic Variants, and White Matter Hyperintensities.
    Mov Disord. 2020 Jun 23. doi: 10.1002/mds.28171.
    PubMed     Abstract available


  374. GIAGKOU N, Maraki MI, Yannakoulia M, Kosmidis MH, et al
    A Prospective Validation of the Updated Movement Disorders Society Research Criteria for Prodromal Parkinson's Disease.
    Mov Disord. 2020 Jun 22. doi: 10.1002/mds.28145.
    PubMed     Abstract available


  375. OJO OO, Abubakar SA, Iwuozo EU, Nwazor EO, et al
    The Nigeria Parkinson Disease Registry: Process, Profile, and Prospects of a Collaborative Project.
    Mov Disord. 2020 Jun 19. doi: 10.1002/mds.28123.
    PubMed     Abstract available


  376. KOULI A, Williams-Gray CH
    Timing Is Everything: The T-Cell Response to alpha-Synuclein Is Maximal in Early Parkinson's.
    Mov Disord. 2020 Jun 19. doi: 10.1002/mds.28122.
    PubMed    


  377. SILVA-BATISTA C, de Lima-Pardini AC, Nucci MP, Coelho DB, et al
    A Randomized, Controlled Trial of Exercise for Parkinsonian Individuals With Freezing of Gait.
    Mov Disord. 2020 Jun 18. doi: 10.1002/mds.28128.
    PubMed     Abstract available


  378. NISHIWAKI H, Ito M, Ishida T, Hamaguchi T, et al
    Meta-Analysis of Gut Dysbiosis in Parkinson's Disease.
    Mov Disord. 2020 Jun 18. doi: 10.1002/mds.28119.
    PubMed     Abstract available


  379. DONADIO V, Incensi A, Rizzo G, De Micco R, et al
    Skin Biopsy May Help to Distinguish Multiple System Atrophy-Parkinsonism from Parkinson's Disease with Orthostatic Hypotension.
    Mov Disord. 2020 Jun 18. doi: 10.1002/mds.28126.
    PubMed     Abstract available


  380. SCHIERDING W, Farrow S, Fadason T, Graham OEE, et al
    Common Variants Coregulate Expression of GBA and Modifier Genes to Delay Parkinson's Disease Onset.
    Mov Disord. 2020 Jun 18. doi: 10.1002/mds.28144.
    PubMed     Abstract available


  381. CHOE CU, Niemann L, Englisch C, Petersen E, et al
    Subclinical Cardiac Microdamage, Motor Severity, and Cognition in Parkinson's Disease.
    Mov Disord. 2020 Jun 17. doi: 10.1002/mds.28129.
    PubMed     Abstract available


  382. JANKOVIC J, Okun MS, Kordower JH
    Stem Cells: Scientific and Ethical Quandaries of a Personalized Approach to Parkinson's Disease.
    Mov Disord. 2020 Jun 12. doi: 10.1002/mds.28187.
    PubMed    


  383. PURRI R, Brennan L, Rick J, Xie SX, et al
    Subjective Cognitive Complaint in Parkinson's Disease Patients with Normal Cognition: Canary in the Coal Mine?
    Mov Disord. 2020 Jun 10. doi: 10.1002/mds.28115.
    PubMed     Abstract available


  384. AIT WAHMANE S, Achbani A, Ouhaz Z, Elatiqi M, et al
    The possible protective role of alpha-synuclein against the SARS-CoV-2 infections in patients with Parkinson's disease.
    Mov Disord. 2020 Jun 9. doi: 10.1002/mds.28185.
    PubMed    


  385. HATTORI N, Kitabayashi H, Kanda T, Nomura T, et al
    A Pooled Analysis From Phase 2b and 3 Studies in Japan of Istradefylline in Parkinson's Disease.
    Mov Disord. 2020 Jun 5. doi: 10.1002/mds.28095.
    PubMed     Abstract available


  386. MARINI K, Mahlknecht P, Tutzer F, Stockner H, et al
    Application of a Simple Parkinson's Disease Risk Score in a Longitudinal Population-Based Cohort.
    Mov Disord. 2020 Jun 3. doi: 10.1002/mds.28127.
    PubMed     Abstract available


  387. VALE TC, Barbosa MT, Franca Resende EP, Silva LC, et al
    No Correlation Between White Matter Changes and Mild Parkinsonian Signs in Individuals Aged Older Than 75 Years.
    Mov Disord. 2020 Jun 3. doi: 10.1002/mds.28120.
    PubMed    


  388. FASANO A, Cereda E, Barichella M, Cassani E, et al
    COVID-19 in Parkinson's Disease Patients Living in Lombardy, Italy.
    Mov Disord. 2020 Jun 2. doi: 10.1002/mds.28176.
    PubMed     Abstract available


  389. POSTUMA RB
    Exercise and Sleep in Parkinson's Disease.
    Mov Disord. 2020;35:918-920.
    PubMed    


  390. MARTINEZ-FERNANDEZ R
    Letter to the Editor: "Subthalamic Nucleus Stimulation Impairs Motivation: Implication for Apathy in Parkinson's Disease".
    Mov Disord. 2020;35:1084.
    PubMed    


  391. GOETZ CG, Stebbins GT, Luo S
    Movement Disorder Society-Unified Parkinson's Disease Rating Scale Use in the Covid-19 Era.
    Mov Disord. 2020;35:911.
    PubMed    


  392. VACHEZ Y, Carcenac C, Magnard R, Goff LK, et al
    Reply to: Letter to the Editor by Martinez-Fernandez.
    Mov Disord. 2020;35:1084-1085.
    PubMed    


    May 2020
  393. NG J, Cortes-Saladelafont E, Abela L, Termsarasab P, et al
    DNAJC6 Mutations Disrupt Dopamine Homeostasis in Juvenile Parkinsonism-Dystonia.
    Mov Disord. 2020 May 30. doi: 10.1002/mds.28063.
    PubMed     Abstract available


  394. MULDERS AEP, van der Velden RMJ, Drukker M, Broen MPG, et al
    Usability of the Experience Sampling Method in Parkinson's Disease on a Group and Individual Level.
    Mov Disord. 2020 May 30. doi: 10.1002/mds.28028.
    PubMed     Abstract available


  395. HALL DA, Nag S, Ouyang B, Bennett DA, et al
    Fragile X Gray Zone Alleles Are Associated With Signs of Parkinsonism and Earlier Death.
    Mov Disord. 2020 May 28. doi: 10.1002/mds.28086.
    PubMed     Abstract available


  396. FABBRI M, Zibetti M, Rizzone MG, Giannini G, et al
    Should We Consider Deep Brain Stimulation Discontinuation in Late-Stage Parkinson's Disease?
    Mov Disord. 2020 May 25. doi: 10.1002/mds.28091.
    PubMed     Abstract available


  397. CILIA R, Bonvegna S, Straccia G, Nico GA, et al
    Effects of COVID-19 on Parkinson's disease clinical features: a community-based case-control study.
    Mov Disord. 2020 May 25. doi: 10.1002/mds.28170.
    PubMed     Abstract available


  398. SHALASH A, Roushdy T, Essam M, Fathy M, et al
    Mental health, physical activity and quality of life in Parkinson's disease during COVID-19 pandemic.
    Mov Disord. 2020 May 19. doi: 10.1002/mds.28134.
    PubMed    


  399. TURNER TH, Dale ML
    Inconsistent Movement Disorders Society-Unified Parkinson's Disease Rating Scale Part III Ratings in the Parkinson's Progression Marker Initiative.
    Mov Disord. 2020 May 18. doi: 10.1002/mds.28108.
    PubMed    


  400. MILOSEVIC L, Scherer M, Cebi I, Guggenberger R, et al
    Online Mapping with the Deep Brain Stimulation Lead: A Novel Targeting Tool in Parkinson's Disease.
    Mov Disord. 2020 May 18. doi: 10.1002/mds.28093.
    PubMed     Abstract available


  401. MARRAS C, Pequeno P, Austin PC, Gershon AS, et al
    Beta Agonists and Progression of Parkinson's Disease in Older Adults: A Retrospective Cohort Study.
    Mov Disord. 2020 May 15. doi: 10.1002/mds.28085.
    PubMed    


  402. CHRISTINE CW, Auinger P, Saleh N, Tian M, et al
    Relationship of Cerebrospinal Fluid Vitamin B12 Status Markers With Parkinson's Disease Progression.
    Mov Disord. 2020 May 14. doi: 10.1002/mds.28073.
    PubMed     Abstract available


  403. CRAIG CE, Jenkinson NJ, Brittain JS, Grothe MJ, et al
    Pedunculopontine Nucleus Microstructure Predicts Postural and Gait Symptoms in Parkinson's Disease.
    Mov Disord. 2020 May 13. doi: 10.1002/mds.28051.
    PubMed     Abstract available


  404. HATTORI N, Mochizuki H, Hasegawa K, Nomoto M, et al
    Ropinirole Patch Versus Placebo, Ropinirole Extended-Release Tablet in Advanced Parkinson's Disease.
    Mov Disord. 2020 May 12. doi: 10.1002/mds.28071.
    PubMed     Abstract available


  405. BOIKA AV
    A postCOVID-19 parkinsonism in the future?
    Mov Disord. 2020 May 12. doi: 10.1002/mds.28117.
    PubMed    


  406. ACHBANI A, Sine H, Naciri A, Baba MA, et al
    Can the 2019 novel coronavirus cause Parkinson's disease?
    Mov Disord. 2020 May 12. doi: 10.1002/mds.28118.
    PubMed    


  407. SALARI M, Zali A, Ashrafi F, Etemadifar M, et al
    Incidence of Anxiety in Parkinson's Disease during Coronavirus disease (COVID-19) pandemic.
    Mov Disord. 2020 May 12. doi: 10.1002/mds.28116.
    PubMed    


  408. BOOT E, Mentzel TQ, Palmer LD, van Harten PN, et al
    Age-Related Parkinsonian Signs in Microdeletion 22q11.2.
    Mov Disord. 2020 May 9. doi: 10.1002/mds.28080.
    PubMed     Abstract available


  409. SCHNEIDER SA, Alcalay RN
    Precision Medicine for Parkinson's Disease: Ambroxol for Glucocerebrosidase-Associated Parkinson's Disease, First Trial Completed.
    Mov Disord. 2020 May 7. doi: 10.1002/mds.28072.
    PubMed    


  410. UCHIDA Y, Kan H, Sakurai K, Inui S, et al
    Magnetic Susceptibility Associates with Dopaminergic Deficits and Cognition in Parkinson's Disease.
    Mov Disord. 2020 May 5. doi: 10.1002/mds.28077.
    PubMed     Abstract available


  411. FAN SP, Lee NC, Lin CH
    Novel Phenotype of 6p25 Deletion Syndrome Presenting Juvenile Parkinsonism and Brain Calcification.
    Mov Disord. 2020 May 5. doi: 10.1002/mds.28079.
    PubMed     Abstract available


  412. PETERS S, Gallo V, Vineis P, Middleton LT, et al
    Alcohol Consumption and Risk of Parkinson's Disease: Data from a Large Prospective European Cohort.
    Mov Disord. 2020 May 1. doi: 10.1002/mds.28039.
    PubMed     Abstract available


  413. HORN MA, Gulberti A, Gulke E, Buhmann C, et al
    A New Stimulation Mode for Deep Brain Stimulation in Parkinson's Disease: Theta Burst Stimulation.
    Mov Disord. 2020 May 1. doi: 10.1002/mds.28083.
    PubMed     Abstract available


  414. HIRSCH EC, Standaert DG
    Ten Unsolved Questions About Neuroinflammation in Parkinson's Disease.
    Mov Disord. 2020 May 1. doi: 10.1002/mds.28075.
    PubMed     Abstract available


  415. TAKESHIGE-AMANO H, Saiki S, Fujimaki M, Ueno SI, et al
    Shared Metabolic Profile of Caffeine in Parkinsonian Disorders.
    Mov Disord. 2020 May 1. doi: 10.1002/mds.28068.
    PubMed     Abstract available


  416. ARCHER DB, Mitchell T, Burciu RG, Yang J, et al
    Magnetic Resonance Imaging and Neurofilament Light in the Differentiation of Parkinsonism.
    Mov Disord. 2020 May 1. doi: 10.1002/mds.28060.
    PubMed     Abstract available


  417. CIRSTEA MS, Yu AC, Golz E, Sundvick K, et al
    Microbiota Composition and Metabolism Are Associated With Gut Function in Parkinson's Disease.
    Mov Disord. 2020 May 1. doi: 10.1002/mds.28052.
    PubMed     Abstract available


  418. BONET-PONCE PHD L, Cookson MR
    Can Leucine-Rich Repeat Kinase 2 Inhibition Benefit GBA-Parkinson's Disease?
    Mov Disord. 2020;35:721-723.
    PubMed    


  419. KIM HJ, Jeon B
    Does Urinary Retention Discriminate Multiple System Atrophy From Parkinson's Disease?
    Mov Disord. 2020;35:901-902.
    PubMed    


  420. CHAUDHURI KR, Jenner P, Antonini A
    Dyskinesia Matters: But Not as Much as It Used to.
    Mov Disord. 2020;35:900-901.
    PubMed    


  421. HAUSER RA, Eidelberg D, Pahwa R, Riggare S, et al
    Reply to: Letter to Editor by Chaudhuri, Jenner, Antonini.
    Mov Disord. 2020;35:901.
    PubMed    


  422. FANCIULLI A, Wenning GK
    Which Autonomic Features Distinguish Multiple System Atrophy and When.
    Mov Disord. 2020;35:902-903.
    PubMed    


  423. ZHANG W, Yang C
    Stem Cell Modeling: A Promising New Avenue for Young-Onset PD Research.
    Mov Disord. 2020;35:759.
    PubMed    


    April 2020
  424. OMER N, Giladi N, Gurevich T, Bar-Shira A, et al
    A Possible Modifying Effect of the G2019S Mutation in the LRRK2 Gene on GBA Parkinson's Disease.
    Mov Disord. 2020 Apr 30. doi: 10.1002/mds.28066.
    PubMed     Abstract available


  425. GALOPPIN M, Berroir P, Soucy JP, Suzuki Y, et al
    Chronic Neuroleptic-Induced Parkinsonism Examined with Positron Emission Tomography.
    Mov Disord. 2020 Apr 30. doi: 10.1002/mds.28046.
    PubMed     Abstract available


  426. WILSON H, Pagano G, de Natale ER, Mansur A, et al
    Mitochondrial Complex 1, Sigma 1, and Synaptic Vesicle 2A in Early Drug-Naive Parkinson's Disease.
    Mov Disord. 2020 Apr 29. doi: 10.1002/mds.28064.
    PubMed     Abstract available


  427. ANTONINI A, Leta V, Teo J, Chaudhuri KR, et al
    Outcome of Parkinson's Disease patients affected by COVID-19.
    Mov Disord. 2020 Apr 29. doi: 10.1002/mds.28104.
    PubMed    


  428. LOPEZ AM, Trujillo P, Hernandez AB, Lin YC, et al
    Structural Correlates of the Sensorimotor Cerebellum in Parkinson's Disease and Essential Tremor.
    Mov Disord. 2020 Apr 28. doi: 10.1002/mds.28044.
    PubMed     Abstract available


  429. WILKE C, Dos Santos MCT, Schulte C, Deuschle C, et al
    Intraindividual Neurofilament Dynamics in Serum Mark the Conversion to Sporadic Parkinson's Disease.
    Mov Disord. 2020 Apr 27. doi: 10.1002/mds.28026.
    PubMed     Abstract available


  430. PRASAD S, Aguirre-Padilla DH, Poon YY, Kalsi-Ryan S, et al
    Spinal Cord Stimulation for Very Advanced Parkinson's Disease: A 1-Year Prospective Trial.
    Mov Disord. 2020 Apr 20. doi: 10.1002/mds.28065.
    PubMed    


  431. PHILLIPPS C, Longato N, Bereau M, Carriere N, et al
    Is Motor Side Onset of Parkinson's Disease a Risk Factor for Developing Impulsive-Compulsive Behavior? A Cross-Sectional Study.
    Mov Disord. 2020 Apr 20. doi: 10.1002/mds.28053.
    PubMed    


  432. PRASAD S, Holla VV, Neeraja K, Surisetti BK, et al
    Parkinson's disease and COVID-19: Perceptions and implications in patients and caregivers.
    Mov Disord. 2020 Apr 17. doi: 10.1002/mds.28088.
    PubMed    


  433. YOO JE, Jang W, Shin DW, Jeong SM, et al
    Timed Up and Go Test and the Risk of Parkinson's Disease: A Nation-wide Retrospective Cohort Study.
    Mov Disord. 2020 Apr 15. doi: 10.1002/mds.28055.
    PubMed     Abstract available


  434. HOPFNER F, Mueller SH, Szymczak S, Junge O, et al
    Rare Variants in Specific Lysosomal Genes Are Associated with Parkinson's Disease.
    Mov Disord. 2020 Apr 8. doi: 10.1002/mds.28037.
    PubMed     Abstract available


  435. OLANOW CW, Standaert DG, Kieburtz K, Viegas T, et al
    Once-Weekly Subcutaneous Delivery of Polymer-Linked Rotigotine (SER-214) Provides Continuous Plasma Levels in Parkinson's Disease Patients.
    Mov Disord. 2020 Apr 6. doi: 10.1002/mds.28027.
    PubMed     Abstract available


  436. PAPA SM, Brundin P, Fung VSC, Kang UJ, et al
    Impact of the COVID-19 pandemic on Parkinson's disease and movement disorders.
    Mov Disord. 2020 Apr 6. doi: 10.1002/mds.28067.
    PubMed    


  437. KARL JA, Ouyang B, Goetz S, Metman LV, et al
    A Novel DBS Paradigm for Axial Features in Parkinson's Disease: A Randomized Crossover Study.
    Mov Disord. 2020 Apr 4. doi: 10.1002/mds.28048.
    PubMed     Abstract available


    March 2020
  438. VIEIRA SRL, Toffoli M, Campbell P, Schapira AHV, et al
    Biofluid Biomarkers in Parkinson's Disease: Clarity Amid Controversy.
    Mov Disord. 2020 Mar 27. doi: 10.1002/mds.28030.
    PubMed    


  439. FEARON C, Farrell MA
    Disease-Specific Strains of alpha-Synuclein in Multiple System Atrophy and Parkinson's Disease: But Why?
    Mov Disord. 2020 Mar 23. doi: 10.1002/mds.28035.
    PubMed    


  440. SVENNINGSSON P, Odin P, Dizdar N, Johansson A, et al
    A Phase 2a Trial Investigating the Safety and Tolerability of the Novel Cortical Enhancer IRL752 in Parkinson's Disease Dementia.
    Mov Disord. 2020 Mar 21. doi: 10.1002/mds.28020.
    PubMed     Abstract available


  441. DONZUSO G, Agosta F, Canu E, Filippi M, et al
    MRI of Motor and Nonmotor Therapy-Induced Complications in Parkinson's Disease.
    Mov Disord. 2020 Mar 17. doi: 10.1002/mds.28025.
    PubMed     Abstract available


  442. LEODORI G, Belvisi D, De Bartolo MI, Fabbrini A, et al
    Re-emergent Tremor in Parkinson's Disease: The Role of the Motor Cortex.
    Mov Disord. 2020 Mar 16. doi: 10.1002/mds.28022.
    PubMed     Abstract available


  443. HIRATA K, Hattori T, Kina S, Chen Q, et al
    Striatal Dopamine Denervation Impairs Gait Automaticity in Drug-Naive Parkinson's Disease Patients.
    Mov Disord. 2020 Mar 12. doi: 10.1002/mds.28024.
    PubMed     Abstract available


  444. PALERMO G, Giannoni S, Frosini D, Morganti R, et al
    Dopamine Transporter, Age, and Motor Complications in Parkinson's Disease: A Clinical and Single-Photon Emission Computed Tomography Study.
    Mov Disord. 2020 Mar 10. doi: 10.1002/mds.28008.
    PubMed     Abstract available


  445. SHIN C, Lim Y, Lim H, Ahn TB, et al
    Plasma Short-Chain Fatty Acids in Patients With Parkinson's Disease.
    Mov Disord. 2020 Mar 10. doi: 10.1002/mds.28016.
    PubMed     Abstract available


  446. NUTT JG, Curtze C, Hiller A, Anderson S, et al
    Aromatic L-Amino Acid Decarboxylase Gene Therapy Enhances Levodopa Response in Parkinson's Disease.
    Mov Disord. 2020 Mar 9. doi: 10.1002/mds.27993.
    PubMed     Abstract available


  447. WIJEYEKOON RS, Moore SF, Farrell K, Breen DP, et al
    Cerebrospinal Fluid Cytokines and Neurodegeneration-Associated Proteins in Parkinson's Disease.
    Mov Disord. 2020 Mar 4. doi: 10.1002/mds.28015.
    PubMed     Abstract available


  448. MOOSA S, Martinez-Fernandez R, Elias WJ, Del Alamo M, et al
    Reply to: Comment on "the role of high-intensity focused ultrasound as a symptomatic treatment for Parkinson's disease".
    Mov Disord. 2020;35:521-522.
    PubMed    


  449. XU Y, He Q, Wang W
    Comment on "The role of high-intensity focused ultrasound as a symptomatic treatment for Parkinson's disease".
    Mov Disord. 2020;35:521.
    PubMed    


  450. CASTILLO-TORRES SA, Sanchez-Cardenas M, Soto-Rincon CA, Chavez-Luevanos B, et al
    Kidney dysfunction and risk of Parkinson's disease: The issue of equations and large numbers.
    Mov Disord. 2020;35:519.
    PubMed    


  451. NAM GE, Kim NH, Han K, Choi KM, et al
    Reply to: Kidney Dysfunction and Risk of Parkinson's Disease: The Issue of Equations and Large Number".
    Mov Disord. 2020;35:520.
    PubMed    


  452. HANUSKA J, Rusz J, Bezdicek O, Dusek P, et al
    Comment on "pro-saccades predict cognitive decline in Parkinson's disease: ICICLE-PD".
    Mov Disord. 2020;35:522.
    PubMed    


    February 2020
  453. CHUNG SJ, Kim HR, Jung JH, Lee PH, et al
    Identifying the Functional Brain Network of Motor Reserve in Early Parkinson's Disease.
    Mov Disord. 2020 Feb 24. doi: 10.1002/mds.28012.
    PubMed     Abstract available


  454. AMARA AW, Wood KH, Joop A, Memon RA, et al
    Randomized, Controlled Trial of Exercise on Objective and Subjective Sleep in Parkinson's Disease.
    Mov Disord. 2020 Feb 24. doi: 10.1002/mds.28009.
    PubMed     Abstract available


  455. ELFIL M, Kamel S, Kandil M, Koo BB, et al
    Implications of the Gut Microbiome in Parkinson's Disease.
    Mov Disord. 2020 Feb 24. doi: 10.1002/mds.28004.
    PubMed     Abstract available


  456. WILLIAMS NM, Hubbard L, Sandor C, Webber C, et al
    Genome-Wide Association Study of Pain in Parkinson's Disease Implicates TRPM8 as a Risk Factor.
    Mov Disord. 2020 Feb 20. doi: 10.1002/mds.28001.
    PubMed    


  457. MIRELMAN A, Hillel I, Rochester L, Del Din S, et al
    Tossing and Turning in Bed: Nocturnal Movements in Parkinson's Disease.
    Mov Disord. 2020 Feb 20. doi: 10.1002/mds.28006.
    PubMed     Abstract available


  458. SIMUNI T, Brumm MC, Uribe L, Caspell-Garcia C, et al
    Clinical and Dopamine Transporter Imaging Characteristics of Leucine- Rich Repeat Kinase 2 (LRRK2) and Glucosylceramidase Beta (GBA) Parkinson's Disease Participants in the Parkinson's Progression Markers Initiative: A Cross-Sectional Study.
    Mov Disord. 2020 Feb 19. doi: 10.1002/mds.27989.
    PubMed     Abstract available


  459. SINGLETON AB, Gasser T
    The Discovery of LRRK2 Mutations as a Cause of Parkinson's Disease.
    Mov Disord. 2020 Feb 17. doi: 10.1002/mds.27999.
    PubMed    


  460. JAFARI Z, Kolb BE, Mohajerani MH
    Auditory Dysfunction in Parkinson's Disease.
    Mov Disord. 2020 Feb 13. doi: 10.1002/mds.28000.
    PubMed     Abstract available


  461. SEO SH, Bacolla A, Yoo D, Koo YJ, et al
    Replication-Based Rearrangements Are a Common Mechanism for SNCA Duplication in Parkinson's Disease.
    Mov Disord. 2020 Feb 10. doi: 10.1002/mds.27998.
    PubMed     Abstract available


  462. LITTLE S, Brown P
    Debugging Adaptive Deep Brain Stimulation for Parkinson's Disease.
    Mov Disord. 2020 Feb 10. doi: 10.1002/mds.27996.
    PubMed     Abstract available


  463. KNOX MG, Adler CH, Shill HA, Driver-Dunckley E, et al
    Neuropathological Findings in Parkinson's Disease With Mild Cognitive Impairment.
    Mov Disord. 2020 Feb 8. doi: 10.1002/mds.27991.
    PubMed     Abstract available


  464. POWELL A, Muller AJ, O'Callaghan C, Sourty M, et al
    Dopamine and Functional Connectivity in Patients With Parkinson's Disease and Visual Hallucinations.
    Mov Disord. 2020 Feb 8. doi: 10.1002/mds.27995.
    PubMed    


  465. PINTER D, Janszky J, Kovacs N
    Comment on "Parkinsonism associated with gabapentinoid drugs: A pharmacoepidemiologic study".
    Mov Disord. 2020;35:375.
    PubMed    


  466. PACHECO-PAEZ T, Montastruc F, Rousseau V, Chebane L, et al
    Reply to: Comment on "Parkinsonism associated with gabapentinoid drugs: A pharmacoepidemiological study".
    Mov Disord. 2020;35:376-377.
    PubMed    


  467. FOLTYNIE T, Athauda D
    Diabetes, BMI, and Parkinson's.
    Mov Disord. 2020;35:201-203.
    PubMed    


  468. PALMA JA
    Renal dysfunction might be a marker of cardiovascular dysautonomia in prodromal alpha-synucleinopathies.
    Mov Disord. 2020;35:374.
    PubMed    


  469. MAHATO AK, Kopra J, Renko JM, Visnapuu T, et al
    Glial cell line-derived neurotrophic factor receptor Rearranged during transfection agonist supports dopamine neurons in Vitro and enhances dopamine release In Vivo.
    Mov Disord. 2020;35:245-255.
    PubMed     Abstract available


  470. RAPPEL P, Grosberg S, Arkadir D, Linetsky E, et al
    Theta-alpha oscillations characterize emotional subregion in the human ventral subthalamic nucleus.
    Mov Disord. 2020;35:337-343.
    PubMed     Abstract available


  471. MARTINEZ E, Pasquereau B, Saga Y, Metereau E, et al
    The anterior caudate nucleus supports impulsive choices triggered by pramipexole.
    Mov Disord. 2020;35:296-305.
    PubMed     Abstract available


  472. LEE JY, Ahn J, Oh S, Shin JY, et al
    Retina thickness as a marker of neurodegeneration in prodromal lewy body disease.
    Mov Disord. 2020;35:349-354.
    PubMed     Abstract available


    January 2020
  473. LEWIS PA, Plun-Favreau H, Rowley M, Spillane J, et al
    Pierre D. and the first photographs of Parkinson's disease.
    Mov Disord. 2020 Jan 24. doi: 10.1002/mds.27965.
    PubMed    


  474. GANG M, Baba T, Hosokai Y, Nishio Y, et al
    Clinical and Cerebral Metabolic Changes in Parkinson's Disease With Basal Forebrain Atrophy.
    Mov Disord. 2020 Jan 23. doi: 10.1002/mds.27988.
    PubMed     Abstract available


  475. BARTH AL, Schneider JS, Johnston TH, Hill MP, et al
    NYX-458 improves cognitive performance in a primate Parkinson's disease model.
    Mov Disord. 2020 Jan 22. doi: 10.1002/mds.27962.
    PubMed     Abstract available


  476. IWAKI H, Blauwendraat C, Makarious MB, Bandres-Ciga S, et al
    Penetrance of Parkinson's Disease in LRRK2 p.G2019S Carriers Is Modified by a Polygenic Risk Score.
    Mov Disord. 2020 Jan 20. doi: 10.1002/mds.27974.
    PubMed     Abstract available


  477. VIJAYAN S, Singh B, Ghosh S, Stell R, et al
    Brainstem ventilatory dysfunction: A plausible mechanism for dyspnea in Parkinson's Disease?
    Mov Disord. 2020 Jan 15. doi: 10.1002/mds.27932.
    PubMed     Abstract available


  478. VACHEZ Y, Carcenac C, Magnard R, Kerkerian-Le Goff L, et al
    Subthalamic nucleus stimulation impairs motivation: Implication for apathy in Parkinson's disease.
    Mov Disord. 2020 Jan 13. doi: 10.1002/mds.27953.
    PubMed     Abstract available


  479. SAMPEDRO F, Marin-Lahoz J, Martinez-Horta S, Perez-Gonzalez R, et al
    CLU rs11136000 promotes early cognitive decline in Parkinson's disease.
    Mov Disord. 2020 Jan 13. doi: 10.1002/mds.27949.
    PubMed     Abstract available


  480. WIRTH T, Mariani LL, Bergant G, Baulac M, et al
    Loss-of-function mutations in NR4A2 cause dopa-responsive dystonia Parkinsonism.
    Mov Disord. 2020 Jan 10. doi: 10.1002/mds.27982.
    PubMed     Abstract available


  481. JI S, Wang C, Qiao H, Gu Z, et al
    Decreased Penetrance of Parkinson's Disease in Elderly Carriers of Glucocerebrosidase Gene L444P/R Mutations: A Community-Based 10-Year Longitudinal Study.
    Mov Disord. 2020 Jan 8. doi: 10.1002/mds.27971.
    PubMed     Abstract available


  482. RANGO M, Dossi G, Squarcina L, Bonifati C, et al
    Brain mitochondrial impairment in early-onset Parkinson's disease with or without PINK1 mutation.
    Mov Disord. 2020 Jan 2. doi: 10.1002/mds.27946.
    PubMed     Abstract available


  483. SANTOS-LOBATO BL, Schumacher-Schuh AF, Tumas V
    Predictors of Motor Complications in Early Parkinson's Disease.
    Mov Disord. 2020;35:191-192.
    PubMed    


  484. BAIG F, Kelly MJ, Lawton MA, Ben-Shlomo Y, et al
    Reply to: "Predictors of motor complications in early Parkinson's disease".
    Mov Disord. 2020;35:193.
    PubMed    


  485. KIM HJ, Mason S, Foltynie T, Winder-Rhodes S, et al
    Motor complications in Parkinson's disease: 13-year follow-up of the CamPaIGN cohort.
    Mov Disord. 2020;35:185-190.
    PubMed     Abstract available


  486. BELLOMO G, Paciotti S, Gatticchi L, Parnetti L, et al
    The vicious cycle between alpha-synuclein aggregation and autophagic-lysosomal dysfunction.
    Mov Disord. 2020;35:34-44.
    PubMed     Abstract available


  487. PYATIGORSKAYA N, Yahia-Cherif L, Gaurav R, Ewenczyk C, et al
    Multimodal Magnetic Resonance Imaging Quantification of Brain Changes in Progressive Supranuclear Palsy.
    Mov Disord. 2020;35:161-170.
    PubMed     Abstract available


  488. COUGHLIN DG, Hurtig HI, Irwin DJ
    Pathological Influences on Clinical Heterogeneity in Lewy Body Diseases.
    Mov Disord. 2020;35:5-19.
    PubMed     Abstract available


  489. CHAUDHURI KR, Schrag A, Weintraub D, Rizos A, et al
    The movement disorder society nonmotor rating scale: Initial validation study.
    Mov Disord. 2020;35:116-133.
    PubMed     Abstract available


  490. RESPONDEK G, Grimm MJ, Piot I, Arzberger T, et al
    Validation of the movement disorder society criteria for the diagnosis of 4-repeat tauopathies.
    Mov Disord. 2020;35:171-176.
    PubMed     Abstract available


  491. ALCALAY RN, Hsieh F, Tengstrand E, Padmanabhan S, et al
    Higher Urine bis(Monoacylglycerol)Phosphate Levels in LRRK2 G2019S Mutation Carriers: Implications for Therapeutic Development.
    Mov Disord. 2020;35:134-141.
    PubMed     Abstract available


    December 2019
  492. GENOUD S, Senior AM, Hare DJ, Double KL, et al
    Meta-analysis of copper and iron in Parkinson's disease brain and biofluids.
    Mov Disord. 2019 Dec 31. doi: 10.1002/mds.27947.
    PubMed     Abstract available


  493. SCHINDLBECK KA, Lucas-Jimenez O, Tang CC, Morbelli S, et al
    Metabolic network abnormalities in drug-naive Parkinson's Disease.
    Mov Disord. 2019 Dec 24. doi: 10.1002/mds.27960.
    PubMed     Abstract available


  494. WHITE RL 3RD, Campbell MC, Yang D, Shannon W, et al
    Little Change in Functional Brain Networks Following Acute Levodopa in Drug-Naive Parkinson's Disease.
    Mov Disord. 2019 Dec 19. doi: 10.1002/mds.27942.
    PubMed     Abstract available


  495. HALL S, Janelidze S, Zetterberg H, Brix B, et al
    Cerebrospinal fluid levels of neurogranin in Parkinsonian disorders.
    Mov Disord. 2019 Dec 13. doi: 10.1002/mds.27950.
    PubMed     Abstract available


  496. WANG Z, Yan J, Wang X, Yuan Y, et al
    Transcranial ultrasound stimulation directly influences the cortical excitability of the motor cortex in Parkinsonian mice.
    Mov Disord. 2019 Dec 12. doi: 10.1002/mds.27952.
    PubMed     Abstract available


  497. CRESSATTI M, Juwara L, Galindez JM, Velly AM, et al
    Salivary microR-153 and microR-223 Levels as Potential Diagnostic Biomarkers of Idiopathic Parkinson's Disease.
    Mov Disord. 2019 Dec 4. doi: 10.1002/mds.27935.
    PubMed     Abstract available


  498. MONJE MHG, Blesa J, Garcia-Cabezas MA, Obeso JA, et al
    Changes in thalamic dopamine innervation in a progressive Parkinson's disease model in monkeys.
    Mov Disord. 2019 Dec 4. doi: 10.1002/mds.27921.
    PubMed     Abstract available


  499. RAVANIDIS S, Bougea A, Papagiannakis N, Maniati M, et al
    Circulating Brain-enriched MicroRNAs for detection and discrimination of idiopathic and genetic Parkinson's disease.
    Mov Disord. 2019 Dec 4. doi: 10.1002/mds.27928.
    PubMed     Abstract available


  500. COSENTINO C, Baccini M, Putzolu M, Ristori D, et al
    Effectiveness of Physiotherapy on Freezing of Gait in Parkinson's Disease: A Systematic Review and Meta-Analyses.
    Mov Disord. 2019 Dec 4. doi: 10.1002/mds.27936.
    PubMed     Abstract available


  501. NEVES MA, Bouca-Machado R, Guerreiro D, Canica V, et al
    Swimming Is Compromised in Parkinson's Disease Patients.
    Mov Disord. 2019 Dec 4. doi: 10.1002/mds.27918.
    PubMed     Abstract available


  502. DE LA CASA-FAGES B, Fernandez-Eulate G, Gamez J, Barahona-Hernando R, et al
    Reply to: "Mitochondrial Parkinsonism due to SPG7/Paraplegin variants with secondary mtDNA depletion".
    Mov Disord. 2019;34:1932-1933.
    PubMed    


  503. REDDY SP, Socal MP, Rieder CRM, Schumacher-Schuh AF, et al
    Parkinson's disease-associated dyskinesia in countries with low access to levodopa-sparing regimens.
    Mov Disord. 2019;34:1929-1930.
    PubMed    


  504. CHAUDHURI KR, Jenner P, Antonini A
    Reply to: "Parkinson disease-associated dyskinesia in countries with low access to levodopa-sparing Regimens".
    Mov Disord. 2019;34:1930-1931.
    PubMed    


  505. FINSTERER J
    Mitochondrial Parkinsonism due to SPG7/Paraplegin variants with secondary mtDNA depletion.
    Mov Disord. 2019;34:1931-1932.
    PubMed    


  506. OBESO JA
    Editor's Note: Deep Brain Stimulation and Functional Neurosurgery for Movement Disorders: Is the Current Cycle Waning?
    Mov Disord. 2019;34:1792-1794.
    PubMed    


    November 2019
  507. LOPEZ G, Steward A, Ryan E, Groden C, et al
    Clinical Evaluation of Sibling Pairs With Gaucher Disease Discordant for Parkinsonism.
    Mov Disord. 2019 Nov 30. doi: 10.1002/mds.27916.
    PubMed     Abstract available


  508. JEONG SM, Han K, Kim D, Rhee SY, et al
    Body mass index, diabetes, and the risk of Parkinson's disease.
    Mov Disord. 2019 Nov 30. doi: 10.1002/mds.27922.
    PubMed     Abstract available


  509. MORALES-BRICENO H, Fung VSC
    Enhancement of glycolysis: A potential disease-modifying strategy for Parkinson's disease.
    Mov Disord. 2019 Nov 29. doi: 10.1002/mds.27934.
    PubMed    


  510. DELGADO-ALVARADO M, Marano M, Santurtun A, Urtiaga-Gallano A, et al
    Nonpharmacological, Nonsurgical Treatments for Freezing of Gait in Parkinson's Disease: A Systematic Review.
    Mov Disord. 2019 Nov 26. doi: 10.1002/mds.27913.
    PubMed     Abstract available


  511. KIM IY, Yang TO, Heath AK, Simpson RF, et al
    Alcohol intake and Parkinson's disease risk in the million women study.
    Mov Disord. 2019 Nov 26. doi: 10.1002/mds.27933.
    PubMed     Abstract available


  512. BETROUNI N, Lopes R, Defebvre L, Leentjens AFG, et al
    Texture features of magnetic resonance images: A marker of slight cognitive deficits in Parkinson's disease.
    Mov Disord. 2019 Nov 23. doi: 10.1002/mds.27931.
    PubMed     Abstract available


  513. MANNE S, Kondru N, Jin H, Anantharam V, et al
    alpha-Synuclein real-time quaking-induced conversion in the submandibular glands of Parkinson's disease patients.
    Mov Disord. 2019 Nov 23. doi: 10.1002/mds.27907.
    PubMed     Abstract available


  514. BARBE MT, Tonder L, Krack P, Debu B, et al
    Deep Brain Stimulation for Freezing of Gait in Parkinson's Disease With Early Motor Complications.
    Mov Disord. 2019 Nov 22. doi: 10.1002/mds.27892.
    PubMed     Abstract available


  515. DI CAPRIO V, Modugno N, Mancini C, Olivola E, et al
    Early-stage Parkinson's patients show selective impairment in reactive but not proactive inhibition.
    Mov Disord. 2019 Nov 21. doi: 10.1002/mds.27920.
    PubMed     Abstract available


  516. BAIANO C, Barone P, Trojano L, Santangelo G, et al
    Prevalence and clinical aspects of mild cognitive impairment in Parkinson's disease: A meta-analysis.
    Mov Disord. 2019 Nov 19. doi: 10.1002/mds.27902.
    PubMed     Abstract available


  517. MERTSALMI TH, Pekkonen E, Scheperjans F
    Antibiotic exposure and risk of Parkinson's disease in finland: A nationwide case-control study.
    Mov Disord. 2019 Nov 18. doi: 10.1002/mds.27924.
    PubMed     Abstract available


  518. OOSTERVELD LP, Verberk IMW, Majbour NK, El-Agnaf OM, et al
    CSF or serum neurofilament light added to alpha-Synuclein panel discriminates Parkinson's from controls.
    Mov Disord. 2019 Nov 18. doi: 10.1002/mds.27897.
    PubMed     Abstract available


  519. PAZ-ALONSO PM, Navalpotro-Gomez I, Boddy P, Dacosta-Aguayo R, et al
    Functional inhibitory control dynamics in impulse control disorders in Parkinson's disease.
    Mov Disord. 2019 Nov 11. doi: 10.1002/mds.27885.
    PubMed     Abstract available


  520. SIDRANSKY E, Arkadir D, Bauer P, Dinur T, et al
    Substrate reduction therapy for GBA1-associated Parkinsonism: Are we betting on the wrong mouse?
    Mov Disord. 2019 Nov 11. doi: 10.1002/mds.27903.
    PubMed    


  521. FANCIULLI A, Goebel G, Lazzeri G, Granata R, et al
    Urinary retention discriminates multiple system atrophy from Parkinson's disease.
    Mov Disord. 2019 Nov 11. doi: 10.1002/mds.27917.
    PubMed    


  522. GILBERT RM, Standaert DG
    Bridging the gaps: More inclusive research needed to fully understand Parkinson's disease.
    Mov Disord. 2019 Nov 11. doi: 10.1002/mds.27906.
    PubMed    


  523. GAJOS KZ, Reinecke K, Donovan M, Stephen CD, et al
    Computer Mouse Use Captures Ataxia and Parkinsonism, Enabling Accurate Measurement and Detection.
    Mov Disord. 2019 Nov 7. doi: 10.1002/mds.27915.
    PubMed     Abstract available


  524. LAWTON M, Baig F, Toulson G, Morovat A, et al
    Blood biomarkers with Parkinson's disease clusters and prognosis: the oxford discovery cohort.
    Mov Disord. 2019 Nov 6. doi: 10.1002/mds.27888.
    PubMed     Abstract available


  525. PETRILLO S, Schirinzi T, Di Lazzaro G, D'Amico J, et al
    Systemic activation of Nrf2 pathway in Parkinson's disease.
    Mov Disord. 2019 Nov 4. doi: 10.1002/mds.27878.
    PubMed     Abstract available


  526. HAQUE ME, Akther M, Jakaria M, Kim IS, et al
    Targeting the microglial NLRP3 inflammasome and its role in Parkinson's disease.
    Mov Disord. 2019 Nov 4. doi: 10.1002/mds.27874.
    PubMed     Abstract available


  527. RAJPUT AH, Rajput EF, Bocking SM, Auer RN, et al
    Reply to: Parkinsonism in essential tremor cases: A clinicopathological study-were they really essential tremor?
    Mov Disord. 2019;34:1750.
    PubMed    


  528. DE PEDRO-CUESTA J, Martinez-Martin P, Calero M, Almazan-Isla J, et al
    Reconciling etiological views on Parkinson's disease.
    Mov Disord. 2019;34:1750-1752.
    PubMed    


  529. MULROY E, Latorre A, Bhatia KP
    Parkinsonism in essential tremor cases: A clinicopathological study-were they really essential tremor?
    Mov Disord. 2019;34:1749.
    PubMed    


  530. RUNDEK T, Shpiner DS, Margolesky J
    Perivascular spaces in basal ganglia - An innocent bystander in Parkinson's disease?
    Mov Disord. 2019;34:1585-1587.
    PubMed    


    October 2019
  531. GILAT M, Coeytaux Jackson A, Marshall NS, Hammond D, et al
    Melatonin for Rapid Eye Movement Sleep Behavior Disorder in Parkinson's Disease: A Randomised Controlled Trial.
    Mov Disord. 2019 Oct 31. doi: 10.1002/mds.27886.
    PubMed     Abstract available


  532. LERCHE S, Wurster I, Roeben B, Zimmermann M, et al
    Parkinson's Disease: Glucocerebrosidase 1 Mutation Severity Is Associated with CSF Alpha-Synuclein Profiles.
    Mov Disord. 2019 Oct 30. doi: 10.1002/mds.27884.
    PubMed     Abstract available


  533. BANDRES-CIGA S, Ahmed S, Sabir MS, Blauwendraat C, et al
    The Genetic Architecture of Parkinson Disease in Spain: Characterizing Population-Specific Risk, Differential Haplotype Structures, and Providing Etiologic Insight.
    Mov Disord. 2019 Oct 29. doi: 10.1002/mds.27864.
    PubMed     Abstract available


  534. NOYCE AJ, Bandres-Ciga S, Kim J, Heilbron K, et al
    The Parkinson's Disease Mendelian Randomization Research Portal.
    Mov Disord. 2019 Oct 28. doi: 10.1002/mds.27873.
    PubMed     Abstract available


  535. HAYAKAWA H, Nakatani R, Ikenaka K, Aguirre C, et al
    Structurally distinct alpha-synuclein fibrils induce robust parkinsonian pathology.
    Mov Disord. 2019 Oct 23. doi: 10.1002/mds.27887.
    PubMed     Abstract available


  536. PRETEGIANI E, Vanegas-Arroyave N, FitzGibbon EJ, Hallett M, et al
    Evidence From Parkinson's Disease That the Superior Colliculus Couples Action and Perception.
    Mov Disord. 2019 Oct 21. doi: 10.1002/mds.27861.
    PubMed     Abstract available


  537. PACHECO-PAEZ T, Montastruc F, Rousseau V, Chebane L, et al
    Parkinsonism associated with gabapentinoid drugs: A pharmacoepidemiologic study.
    Mov Disord. 2019 Oct 21. doi: 10.1002/mds.27876.
    PubMed     Abstract available


  538. MORALES-BRICENO H, Mahant N, Ha AD, Chang FCF, et al
    Long-term safety and efficacy of 24-hour levodopa-carbidopa intestinal gel in Parkinson's disease.
    Mov Disord. 2019 Oct 11. doi: 10.1002/mds.27883.
    PubMed    


  539. KOLMANCIC K, Perellon-Alfonso R, Pirtosek Z, Rothwell JC, et al
    Sex differences in Parkinson's disease: A transcranial magnetic stimulation study.
    Mov Disord. 2019 Oct 11. doi: 10.1002/mds.27870.
    PubMed     Abstract available


  540. VAN DER VEEN S, Zutt R, Klein C, Marras C, et al
    Nomenclature of Genetically Determined Myoclonus Syndromes: Recommendations of the International Parkinson and Movement Disorder Society Task Force.
    Mov Disord. 2019 Oct 4. doi: 10.1002/mds.27828.
    PubMed     Abstract available


  541. SACHELI MA, Neva JL, Lakhani B, Murray DK, et al
    Exercise increases caudate dopamine release and ventral striatal activation in Parkinson's disease.
    Mov Disord. 2019 Oct 4. doi: 10.1002/mds.27865.
    PubMed     Abstract available



  542. Abstracts of the 2019 International Congress of the Parkinson's Disease and Movement Disorders(R).
    Mov Disord. 2019;34 Suppl 2:S1-S930.
    PubMed    


  543. HONKANEN EA, Saari L, Orte K, Gardberg M, et al
    Reply to: The time delay between in vivo imaging and postmortem data poses a caveat on "no link" findings.
    Mov Disord. 2019;34:1580-1581.
    PubMed    


  544. PIFL C
    The time delay between in vivo imaging and postmortem data poses a caveat on "no link" findings.
    Mov Disord. 2019;34:1579-1580.
    PubMed    


    September 2019
  545. BOUTHOUR W, Bereau M, Kibleur A, Zacharia A, et al
    Dyskinesia-inducing lead contacts optimize outcome of subthalamic stimulation in Parkinson's disease.
    Mov Disord. 2019 Sep 30. doi: 10.1002/mds.27853.
    PubMed     Abstract available


  546. DAYAL V, Grover T, Tripoliti E, Milabo C, et al
    Short Versus Conventional Pulse-Width Deep Brain Stimulation in Parkinson's Disease: A Randomized Crossover Comparison.
    Mov Disord. 2019 Sep 30. doi: 10.1002/mds.27863.
    PubMed     Abstract available


    July 2019
  547. MORALES-BRICENO H, Fung VSC
    You shall not pass! Gut bacteria can convert levodopa to dopamine.
    Mov Disord. 2019;34:986.
    PubMed    


  548. LATORRE A, Rocchi L, Berardelli A, Bhatia KP, et al
    The interindividual variability of transcranial magnetic stimulation effects: Implications for diagnostic use in movement disorders.
    Mov Disord. 2019;34:936-949.
    PubMed     Abstract available


  549. HINKLE JT, Dawson VL, Dawson TM
    The A1 astrocyte paradigm: New avenues for pharmacological intervention in neurodegeneration.
    Mov Disord. 2019;34:959-969.
    PubMed     Abstract available


  550. KRISMER F, Seppi K, Gobel G, Steiger R, et al
    Morphometric MRI profiles of multiple system atrophy variants and implications for differential diagnosis.
    Mov Disord. 2019;34:1041-1048.
    PubMed     Abstract available


    June 2019
  551. OLANOW CW
    Levodopa is the best symptomatic therapy for PD: Nothing more, nothing less.
    Mov Disord. 2019;34:812-815.
    PubMed    


    May 2019
  552. LI J, Dauer W
    Cholinergic interneurons drive maladaptive changes in thalamostriatal circuitry after dopamine depletion.
    Mov Disord. 2019;34:682.
    PubMed    


    April 2019
  553. KISHORE A, Ashok Kumar Sreelatha A, Sturm M, von-Zweydorf F, et al
    Understanding the role of genetic variability in LRRK2 in Indian population.
    Mov Disord. 2019;34:496-505.
    PubMed     Abstract available


    March 2019
  554. BREEN DP, Halliday GM, Lang AE
    Gut-brain axis and the spread of alpha-synuclein pathology: Vagal highway or dead end?
    Mov Disord. 2019;34:307-316.
    PubMed     Abstract available


  555. ARENS J, Storzer L, Hirschmann J, Dalal SS, et al
    Freezing of gait does not modulate beta oscillations in mesial cortical motor areas.
    Mov Disord. 2019;34:436.
    PubMed    


    February 2019
  556. ROSS GW, Abbott RD, Petrovitch H, Duda JE, et al
    Association of brain heptachlor epoxide and other organochlorine compounds with lewy pathology.
    Mov Disord. 2019;34:228-235.
    PubMed     Abstract available


  557. SEBILLE SB, Rolland AS, Faillot M, Perez-Garcia F, et al
    Normal and pathological neuronal distribution of the human mesencephalic locomotor region.
    Mov Disord. 2019;34:218-227.
    PubMed     Abstract available


    January 2019
  558. HOMAYOON N, Pirpamer L, Franthal S, Katschnig-Winter P, et al
    Nigral iron deposition in common tremor disorders.
    Mov Disord. 2019;34:129-132.
    PubMed     Abstract available


  559. WHITWELL JL, Tosakulwong N, Schwarz CG, Botha H, et al
    MRI Outperforms [18F]AV-1451 PET as a Longitudinal Biomarker in Progressive Supranuclear Palsy.
    Mov Disord. 2019;34:105-113.
    PubMed     Abstract available


  560. HARRIS M, Steele J, Williams R, Pinkston J, et al
    MRI-guided laser interstitial thermal thalamotomy for medically intractable tremor disorders.
    Mov Disord. 2019;34:124-129.
    PubMed     Abstract available


  561. FISCHER DL, Sortwell CE
    BDNF provides many routes toward STN DBS-mediated disease modification.
    Mov Disord. 2019;34:22-34.
    PubMed     Abstract available


  562. HARMSEN IE, Lee DJ, Dallapiazza RF, De Vloo P, et al
    Ultra-high-frequency deep brain stimulation at 10,000 Hz improves motor function.
    Mov Disord. 2019;34:146-148.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Parkinson's Disease is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: